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The research described in this thesis was based on two groups of patients. The 
first cohort of patients (62) was from a combined University of Virginia – Groote 
Schuur Hospital Pituitary Apoplexy Database, on an Internet website, set up by 
myself and the Department of Neurosurgery, University of Virginia. I did the 
analysis of data from the combined database. The research on the second cohort of 
patients (38) was undertaken by myself in the Department of Neurosurgery at 
University of Virginia. I traveled to the University of Virginia, Charlottesville, 
Virginia, USA, with the express purpose of doing the research. The concept of 
using histopathology to predict outcome, comparing Magnetic Resonance Imaging 
(MRI) to histopathology findings and using precipitating factors to predict 
outcome were all my original thoughts. Professor Laws gave me support, advice 






Pituitary apoplexy is an uncommon, yet potentially fatal illness, usually the result 
of infarction, hemorrhage or a combination of both in a pituitary tumor. The 
management of pituitary apoplexy consists of replacement therapy and in the 
majority of patients, surgical decompression, although some cases may be treated 
conservatively.  Up to now no study has attempted to separate the two 
histopathological types of pituitary apoplexy or to analyze their clinical and 
radiological significance on presentation and outcome. 
 
The University of Virginia – Groote Schuur Hospital Pituitary Apoplexy Database 
(UVA-GSH Pituitary Apoplexy Database), an Internet website, was set up and 62 
patients entered to combine both centers experience. The presentation, clinical 
features, endocrine status, management and outcome were reviewed 
retrospectively. The 59 patients in whom histopathology reports were available 
were then divided into two groups: 1. those in whom infarction alone was present 
(22 patients) and; 2. those in who hemorrhage alone or mixed hemorrhage and 
infarction were found  (37 patients) at histopathological examination. The time to 
presentation, severity of clinical presentation, outcome and endocrine status 
between the two histopathological groups were compared. The patients in whom 
infarction alone was found on histopathological examination had a longer course 
prior to presentation, significantly less severe clinical features on presentation and 
 xiv 
a significantly better outcome than those presenting with hemorrhage or 
hemorrhagic infarction. The endocrine requirements were similar in both groups. 
 
The discriminative ability of MRI to distinguish infarction alone form hemorrhage 
or hemorrhagic infarction was analyzed in an attempt to prognosticate outcome. A 
group of 36 consecutive patients from UVA (1996-2006), in whom pre-operative 
MRI was carried out, were divided into the two histopathological groupings. The 
MRI findings were reviewed blindly and divided into pituitary tumor alone, 
infarction alone and hemorrhage or hemorrhagic infarction, and were then 
correlated with the histopathological groups. The MRI scans were able to predict 
the histopathology accurately in the majority of cases (CI = 95%). The MRI was 
therefore able to predict the histopathological findings and consequently the 
severity of presentation and outcome.  
 
In the same cohort of patients those (9 patients) in whom precipitating factors 
were identified were investigated to assess whether the presence of precipitating 
factors had an influence on outcome. The majority of patients in whom 
precipitating factors were identified (8 / 9 patients), were 13.1 times more likely to 
have hemorrhage or hemorrhagic infarction on histopathology. 
 
In conclusion patients in whom the histopathological studies show infarction only 
have a longer presentation period, less severe clinical features and better outcome 
than those with hemorrhage or hemorrhagic infarction. The histopathology and 
consequently the severity of clinical findings and outcome may be predicted in the 
majority of patients on the MRI. In addition the presence of a precipitating factor 
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appears to make the likelihood of a histopathological finding hemorrhage or 
hemorrhagic infarction greater. These findings may prove useful in managing 
patients and predicting outcome for patients and families, as well as facilitating a 








1.1 Historical perspective of pituitary apoplexy. 
 
In 1898 Bailey, a neurologist from New York City described the first clinical case of 
pituitary apoplexy when he documented the catastrophic results of a hemorrhage in a 
pituitary adenoma in a patient with acromegaly [Bailey 1898]. In 1905 Bleibtrou 
found old hemorrhage in a pituitary adenoma at post mortem in a young man with 
acromegaly [Bleibtreu 1905]. In 1913 Monro described a patient who clinically 
appeared to have had a pituitary apoplexy, resulting in rapid demise, and at post 
mortem was found to have a large pituitary adenoma that, although it had no 
hemorrhage, was described as edematous and necrotic [Munro 1913]. Dingley and 
Lond published, in 1932, a report of a patient previously well who suddenly collapsed 
and died and who at post-mortem examination was found to have a large pituitary 
adenoma with old hemorrhage as well as a considerable amount of fresh hemorrhage 
within it [Dingley & Lond 1933]. However, it was only in 1950 that Brougham et al 
first coined the phase “pituitary apoplexy”. They published a series of 5 patients who 
had died and at post-mortem findings of hemorrhage and  / or extensive necrosis of a 
pituitary adenoma were found. These patients had presented with a fairly uniform 
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syndrome consisting of drowsiness, coma, headache, neck stiffness, ocular palsies and 
sometimes hemiparesis [Brougham et al 1950]. 
 
Subsequent to these early reports there have been numerous case reports and series 
published on patients with pituitary apoplexy resulting in an improved understanding 
of the clinical syndrome and the associated pathological features.  Rovitt et al 
reported 9 patients in whom pituitary apoplexy was the presenting feature of their 
pituitary adenoma  [Rovitt & Fein 1972]. In 1981 Wakai et al reported 51 cases of 
pituitary apoplexy that were symptomatic and had been treated in their department 
[Wakai et al 1981].  Mohr and Hardy reported 4 patients with pituitary apoplexy that 
were treated by them between 1962 and 1979 [Mohr & Hardy 1982]. Ebersold and 
co-workers managed 11 patients with pituitary apoplexy at the Mayo Clinic in a busy 
neuroendocrine service where 940 pituitary tumors were operated on between 1972 
and 1982 [Ebersold et al 1983]. Sixteen patients were diagnosed and treated for 
pituitary apoplexy over a 10-year period by Onesti [Onesti et al 1990]. Between 1975 
and 1991 38 patients were managed surgically by Bills et al [Bills et al 1993]. 
Randeva and co-workers reported on 35 patients treated at the Radcliffe Infirmary, 
Oxford over an 11-year period [Randeva et al 1999].  
 
Transsphenoidal surgery and corticosteroid replacement is generally accepted as the 
optimal management, although there is a body of opinion in the literature favoring 
conservative management in carefully selected patients [Rovitt & Fine 1972, Wakai et 
al 1981, Mohr & Hardy 1982, Ebershold et al 1983, Onesti et al 1990, Bills et al 
1993, Randeva et al 1999]. Despite the improvements in both the medical and surgical 
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management of this condition it remains a poorly understood and frequently 
undiagnosed with potentially fatal implications. 
 
1.2 Definition and incidence of pituitary apoplexy 
 
The term “apoplexy” is derived from the Greek apo – from, off – and plessein – to 
strike, to disable by stroke [Cardoso &Peterson 1984].  The reported incidence of 
pituitary apoplexy varies from 0.6% - 25.7%. The reason for this wide variation is 
largely related to the lack of uniformity in the definition of pituitary apoplexy.  
 
Moharty and co-workers reviewed the histopathology of 70 resected pituitary tumors. 
They found in 18 of these tumors (25.7%) there was evidence of hemorrhage on 
histopathological examination, but 11 of these patients did not have any clinical 
apoplectic event [Moharty et al 1977]. Findling noted that spontaneous infarction of 
microadenomas may be subclinical resulting in improvement of pituitary hormone 
hyperscretion without impairment of other anterior pituitary hormone secretion 
[Findling et al 1981]. Mohr and Hardy attempted to assess the significance of necrosis 
and hemorrhage in patients with pituitary adenomas operated on by them from 1962 
to 1979. They found that the clinical picture of pituitary apoplexy was present in only 
4 (0.6%) of the 663 cases but necrosis or hemorrhage was found on histopathological 
examination in 9.5% of cases [Mohr & Hardy 1982]. In 1981 Wakai et al published at 
that time the largest series of patients presenting with pituitary apoplexy. In a series of 
560 patients operated on for pituitary adenomas they found hemorrhage, old or new, 
visualized at operation in 90 (16.6%). Thirty eight patients (6.8%) were described as 
having a “major attack” – history and clinical findings consistent with pituitary 
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apoplexy; 13 (2.3%) a “minor attack” with symptoms but no clinical findings 
consistent with apoplexy; and 42 patients (7.5%) were found to have asymptomatic 
hemorrhage [Wakai et al 1981]. Ebershold and colleagues reporting on their 
experience with 940 pituitary adenomas operated on found only 11 of these to have 
presented with pituitary apoplexy.  Their criteria for inclusion were sudden onset of 
neurological symptoms and signs in a patient previously asymptomatic or with prior 
signs of a pituitary adenoma associated with hemorrhage or necrosis within a 
surgically removed pituitary adenoma [Ebersold et al 1983]. Ostrov et al reviewed the 
clinical presentations, Computed Tomography (CT) scans, Magnetic Resonance 
Imagining (MRI) scans and findings at surgery to determine the clinical significance 
of suspected intratumoral hemorrhage in pituitary adenomas. They concluded that 
intratumoral hemorrhage is not synonymous with pituitary apoplexy and only 3 of 
their patients with intrasellar hemorrhage had clinical apoplexy [Ostrov et al, 1989]. 
Onesti and colleagues reported on 16 patients over a 10-year period with clinical 
pituitary apoplexy that had hemorrhage confirmed at surgery and on histopathological 
examination. During the same period 5 patients were operated on who had large 
hemorrhages into the pituitary tumors, but had no clinical symptoms of pituitary 
apoplexy. They described these patients as having subclinical pituitary apoplexy 
[Onesti et al, 1990]. Thirty-seven patients were treated neurosurgically by Bills and 
colleagues between 1975 and 1991 for pituitary apoplexy. They defined pituitary 
apoplexy as a patient who had an abrupt onset of severe headache or visual 
disturbances in the presence of a pituitary adenoma. During the same period 2034 
pituitary adenomas were treated surgically, therefore the incidence of apoplexy in 
their series was 1.6% [Bills et al 1993]. Randeva et al used the same inclusion criteria 
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as Bills et al for patients with pituitary apoplexy in their series and published an 
incidence of 3.2% [Randeva et al 1999].  
 
The highly variable incidence of pituitary apoplexy reported is therefore related to the 
unclear definition of pituitary apoplexy. The term pituitary apoplexy has also been 
used to describe the sudden infarction of nontumorous pituitary glands initially 
described by Simmonds as well as Sheehan and Summers [Simmonds 1914, Sheehan 
& Summers 1949, Conomy et al 1974, Reid et al 1985]. The term subclinical pituitary 
apoplexy has been used to describe asymptomatic hemorrhage or infarction in a 
pituitary tumor [David et al 1975, Findling et al 1981]. However this is not 
descriptive of a clinical syndrome at all, is potentially confusing and may best be 
discarded. The term tumor “burn-out” has been used to describe the event of a 
secreting tumor spontaneously being cured by a hemorrhage or necrosis occurring 
within that pituitary adenoma [Males & Townsend 1972, Laws 1979, Mohr & Hardy 
1982].  
 
The definition now most universally agreed upon is that pituitary apoplexy is a 
clinical syndrome resulting from hemorrhage, infarction, or hemorrhagic infarction of 
a pituitary tumor that results in its sudden and fulminant expansion. Apoplexy is of 
sudden onset and may be characterized by sudden headache, visual disturbance, 
opthalmoplegia, pituitary hypofunction, physical collapse, impaired level of 
consciousness, and death [Cardoso & Petersen 1984, Dubuisson et al 2006, Nawar et 
al 2008, Randeva et al 1999, Verrees et al 2004]. Using this definition of pituitary 
apoplexy the incidence is 0.6% - 3.2% making pituitary apoplexy an uncommon 
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occurrence  [Mohr & Hardy 1982, Wakai et al 1981, Ebershold et al 1983, Onesti et al 
1990, Bills et al 1993, Randeva et al 1999, Dubuisson et al 2006]. 
 
1.3 Age and gender distribution 
 
The age of patients in which pituitary apoplexy occurs does not appear to differ from 
that in which pituitary adenomas are diagnosed. Reid et al described an even 
distribution between 20 and 70 years [Reid et al 1985]. Wakai et al reported a mean 
age of 35.5 years with a range from 16 to 63 years, however their series of patients 
appears to be younger than other reported series [Wakai et al 1981]. The most 
commonly reported mean age is in the 5th and 6th decades: Bills reported a mean age 
of 56.6 years; Duboisson 56 years; Onesti 49 years and Randeva 49.8 years [Bills et al 
1993, Duboisson et al 2006, Onesti et al 1990, Randeva et al 1999]. The series of 
Wakai and colleagues and Onesti and co-workers described pituitary apoplexy 
occurring with equal frequency in both sexes. However in the majority of published 
series there is a preponderance of males to female in the approximate ratio of 2:1 
[Bills et al 1993, Duboisson et al 2006, Ebersold et al 1983, Randeva et al 1999, Reid 
et al 1985 Rovit & Fein 1972]. 
 
1.4 The vascular supply of the pituitary stalk and gland 
 
The arterial blood supply to the pituitary stalk and gland arise from the supraclinoid 
and cavernous portions of the internal carotid artery bilaterally. The superior 
hypophyseal artery arises from the supraclinoid internal carotid artery just as it 
emerges from the dura mater covering the cavernous sinus. The superior hypophyseal 
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artery usually arises as two or three small trunks on the medial aspect of the internal 
carotid artery and run upwards and medially to the tuber cinereum where it joins its 
contralateral fellow and forms a plexus around the hypophyseal stalk – the 
circuminfundibular network [Baker 1971, Pribram et al 1966] Each superior 
hypophyseal artery sends branches to the optic nerve, optic chiasm, the ventral 
hypothalamus and upper portion of the pituitary stalk before giving off a major 
branch, the trabecular artery that descends alongside the infundibulum to supply the 
lower infundibulum and pierce the substance of the anterior lobe [Gibo et al 1994, 
Reid et al 1985, Warwick & Williams 1973].  This branch courses through the pars 
distalis to supply the lower infundibular stalk and anastoamose with the vascular ring 
formed by the inferior hypophyseal artery [Reid et al].  
 
The inferior hypophyseal artery arises from a common trunk – the 
meningohypophyseal trunk - at the junction of the proximal vertical and horizontal 
segments of the cavernous internal carotid artery [Pribham et al 1966]. The inferior 
hypophyseal artery, usually the largest of the 3 branches passes upwards and medially 
to reach the lateral surface of the neurohypophysis where it divides into superior and 
inferior divisions, which run in the sulcus between the anterior and posterior lobes of 
the pituitary. Each division anastomoses with its partner from the opposite side, 
forming an arterial circle from which many tiny arteries penetrate directly into the 
substance of the posterior lobe to form a rich capillary network – the inferior 
hypophyseal arterial circle or inferior capsular arterial rete [Baker 1972, Gibo et al 
1994].   
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There is some difference of opinion in the blood supply to the pars distalis (anterior 
lobe) of the pituitary. Some investigators believe there is no direct blood supply to 
pars distalis and all blood flow is via the portal capillaries [McConnell 1953, Rovitt & 
Fein 1972]. However, it is now believed small arterial branches to the upper half of 
the anterior pituitary from the trabecular and inferior hypophyseal arteries may also 
contribute and may account for some sparing of the anterior pituitary in postpartum 
pituitary necrosis [Reid et al 1986]. The hypophyseal portal system is an extensive 
capillary network originating from the superior and inferior hypophyseal vessels in 
the infundibular stem. The arteries in the median eminence and upper and lower 
infundibulum end in characteristic tufts of capillaries. These tufts drain in descending 
vessels, which break up into vascular sinusoids between the secretory clumps of the 
pars anterior and supply virtually the whole blood supply to this area. These portal 
vessels may be divided into two groups: the long portal vessels and the short portal 
vessels. The long portal vessels drain the median eminence and upper infundibulum 
arising from the superior hypophyseal artery branches. These capillaries have scant 
innervation, are surrounded by poorly developed stroma and their endothelial lining is 
richly fenestrated and lacks the features of the blood-brain barrier. The short portal 
vessels drain the lower infundibulum and mainly arise from the inferior hypophyseal 
artery branches. The inferior artery and its branches are richly innervated, but the 
capillary bed is irrigated by it (short portal vessels) and also lacks the blood-brain 
barrier [Cardoso & Peterson 1984, Warwick &Williams 1973]. The venous drainage 
from the anterior lobe is through a series of veins that penetrate the capsule all over 
the surface of the gland and enter the neighboring venous sinuses. The portal vessels 
are of great functional significance, carrying hormone releasing factors elaborated in 
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the parvocellular groups of hypothalamic neurons and which control the secretory 













1.5 The anatomical relations of the pituitary gland 
 
The pituitary gland is located below the brain in the centre of the skull base. Below 
the pituitary gland is the body of the sphenoid containing the right and left sphenoid 
sinuses; behind is the dorsum sellae, basilar artery and brainstem; lateral are the left 
and right cavernous sinuses and their contents: and above is the diaphragma sellae 
separating the hypophysis from the optic chiasm and the interpeduncular cistern 














The body of the sphenoid bone is in intimate contact with the nasal cavity below and 
the pituitary gland above. The body of the sphenoid bone is cuboidal in shape and 
contains the sphenoid sinus. The pituitary fossa occupies the central part of the body 
of the sphenoid bone and is bounded anteriorly by the tuberculum sellae and 
posteriorly by the dorsum sellae. The upper limit of the normal size of the pituitary 
fossa is 13mm in depth, 17mm in length and 15 mm in width [Bergland et al 1968, 
Quaknine & Hardy 1987, Rhoton 2002]. The sphenoid sinus separates the pituitary 
gland from the nasal cavity and is subject to considerable variation in size, shape and 
degree of pneumatization. The are three different types of sphenoid sinus present in 
the adult: in the conchal type the area below the sellar is a solid block of bone without 
any pneumatization; in the presellar type the pneumatization does not extend beyond 
the vertical plane parallel to the anterior sellar wall; and in the sellar type of sphenoid 
sinus, the most common, the air cavity extends into the body of the sphenoid sinus 
below the pituitary fossa as far posteriorly as the clivus [Rhoton 2002]. The septae 
within the sphenoid sinus are highly variable. The carotid sulcus produces a 
prominence within the sinus wall below the floor and anterior margin of the sella – 
this prominence is variable in size. 
 
The diaphragma sellae forms the roof of the sella turcica, covering the pituitary gland 
except for a small central opening through which the pituitary stalk projects. The 
diaphragma tends to be thinner around the infundibulum than at the periphery. There 
is usually a separation between lateral surface of the gland and the carotid artery 
although in 25% of cases the carotid artery will project through the medial wall of the 
cavernous sinus to indent the pituitary gland [Rhoton 2002]. Intercavernous sinuses 
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connecting the two cavernous sinuses can occur anteriorly, inferiorly, and posteriorly 
to the gland or may be absent. 
 
The cavernous sinuses are located on each side of the sphenoid sinus, sella and 
pituitary gland. They extend from the superior orbital fissure to the petrous apex. The 
medial wall of the cavernous sinus forms the lateral margin of the sella [Yasuda et al 
2004]. The horizontal portion of the carotid artery is surrounded by the cavernous 
sinus. The carotid artery enters the cavernous sinus lateral to the posterior clinoid 
process where it leaves foramen lacerum and exits along the medial side of the 
cavernous sinus where it penetrates the roof of the cavernous sinus. The oculomotor, 
trochlear and ophthalmic nerves lie from superior to inferior between the two dural 
leaves of the lateral sinus wall The abducens courses within the cavernous sinus 
medial to the ophthalmic nerve and is adherent to the lateral aspect of the carotid 
artery. 
 
The suprasellar area corresponds to the anterior incisural space between the free edges 
of the tentorium and the front of the midbrain. This area is occupied by the optic 
chiasm, circle of Willis and hypothalamus. The optic chiasm is situated at the junction 
of the anterior wall and floor of hypothalamus. It is situated above the diaphragma 
sellae and pituitary gland. The anterior cerebral arteries, anterior communicating 
artery, lamina terminalis and third ventricle are located above the chiasm. This area 
contains all the components of the circle of Willis: the basilar artery and posterior part 
of the circle of Willis are located in the anterior incisural space below the floor of the 
third ventricle; the anterior part of the circle of Willis including the anterior cerebral 
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and anterior communicating arteries are intimately related to the anterior wall of the 
third ventricle [Rhoton 2002]. 
 
1.6 Aims of present study 
 
a. Review a large contemporary series of patients with pituitary apoplexy from 
University of Virginia, Charlottesville, USA and University of Cape Town, 
South Africa. The differential diagnosis, clinical presentation, diagnosis, 
treatment and outcome are assessed (Chapter 2). 
b. Analyze the histolopathological studies of patients with pituitary apoplexy that 
were divided into two groups: 1. hemorrhage or hemorrhagic infarction and 2. 
infarction alone. The clinical presentation and outcome of the patients in the 
two different histopathological groups were compared to assess if there was 
any difference between them (Chapter 3). 
c. Review MRI studies on consecutive patients to assess if the histopathology 
found at surgery could be predicted reliably on the MRI scan done pre-
operatively. In this way it would be possible to predict the severity of the 
presentation and outcome on the MRI scan done at the time of diagnosis 
(Chapter 4). 
d. Determine the clinical relevance of the precipitating factors in patients with 
pituitary apoplexy. Assess whether any particular histological group was 
found more commonly in patients with known precipitating factors and 








PITUITARY APOPLEXY: A CO-OPERATIVE STUDY 




A large contemporary series of patients with pituitary apoplexy from University of 
Virginia, Charlottesville, Virginia, USA and University of Cape Town, Cape Town 
South Africa is reviewed. The differential diagnosis, clinical presentation, diagnosis, 
treatment and outcome are assessed. 
 
2.2 Patients and methods 
 
The Departments of Neurosurgery at the University of Virginia (UVA), 
Charlottesville, Virginia, USA and Groote Schuur Hospital (GSH), University of 
Cape Town, Cape Town, South Africa co-operatively combined their experience in a 
retrospective series of patients who were treated for pituitary apoplexy. A combined 
UVA-GSH Health Insurance Portability and Accountability Act-compatible database 
was developed using a website (UVA-GSH Pituitary Apoplexy Database) designed 
by UVA and based on a common protocol. An investigator from each institution, 
using password protection, was able to access the UVA-GSH Pituitary Apoplexy 
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Database website and enter data for each patient. The captured data on the patients 
was then retrospectively analyzed. 
 
The definition of pituitary apoplexy used for entry of patients into the study included 
a history and clinical features consistent with pituitary apoplexy; appropriate findings 
on imaging; and histological confirmation of hemorrhage, infarction, or both. Three 
patients, however, were treated conservatively, and in them, the diagnosis was made 
on the basis of the clinical picture and Magnetic Resonance Imaging (MRI) features 
of pituitary apoplexy. Thirty-eight consecutive patients from the period 1970 to 2003 
treated by two surgeons at GSH were entered into the study. Twenty-four patients 
treated by a single surgeon at UVA from 1992 to 2003 were entered. During the same 
period a total of 586 patients at GSH and 1019 patients at UVA were operated on for 
pituitary tumors at both institutions. 
 
Information entered into the database included presentation, possible precipitating 
factors, imaging, endocrine investigations, findings at surgery, surgical approach, 




Sixty-two patients were entered into the study. The mean age was 51.6 years with a 
range of 18-82 years. Men were in the majority, with 38 men (61%) compared with 




2.3.1 Presentation and clinical findings 
 
The average length of time from onset of symptoms until presentation in the 
neurosurgery department was 14.2 days, with a range from just a few hours to 80 
days. Fifty (81%) patients had no previous history of a pituitary tumor or known 
endocrine dysfunction, 8 (13%) had a known pituitary tumor but had not undergone 
surgery, and only 4 (5%) had previously had surgery for a pituitary adenoma. The 
most common differential diagnosis entertained was subarachnoid hemorrhage (40 
patients), followed by meningitis (19 patients), with syncope and myocardial 
infarction being uncommon (1 patient each). In 96% of patients, no precipitating 
factor was identified. Radiotherapy, cardiac surgery, and head trauma were identified 
as precipitating factors in a single patient each. 
 
Headache, typically of sudden onset, was the presenting complaint in 52 patients 
(84%) and was accompanied by nausea or vomiting in 15 patients. Eight patients 
(13%) had a diminished level of consciousness at presentation, and two of these were 
in a coma (1 of these was in coma after cardiac surgery and later was found to be 
blind, so it is uncertain whether the coma was the result of cardiac surgery or pituitary 
apoplexy). Twenty-six patients (42%) complained of decreased visual acuity or visual 
fields, and 6 (10%) presented with bilateral blindness. Twenty-three patients (37%) 
had diplopia or other symptoms related to cranial nerve dysfunction at presentation. 
Six patients complained of fatigue and lethargy, and 2 had amenorrhea. Seventeen of 
the patients had a history of previous endocrine-related symptoms 
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The average Glasgow Coma Score was 14, although the majority (n=54) had a GCS 
of 15. Visual acuity was normal in 22 patients (39%), reduced but functional in 25 
(44%), reduced and non-functional in 4 (7%), and blind in 6 (10%). In 5 patients, the 
visual status was unknown. Bitemporal hemianopia was found in 21 patients (43%), 
although in 13 patients visual fields could not be tested or were unknown. Cranial 
nerve abnormalities were present in 26 patients (43%): oculomotor palsies in 12 
(20%), abducent nerve palsy in 3 (5%), and multiple cranial nerve palsies in 11 
(18%). In 2 patients, the cranial nerve function was unknown. Long-tract signs 
(hemiplegia) were present in 2 patients. Seventeen of the patients had a history of 





Figure 2.1: Clinical features in 62 patients with pituitary apoplexy. H= headache, 
LOC = diminished level of consciousness, VA = diminished visual acuity, VF = 























MRI has become the imaging modality of choice in pituitary tumors, and 
consequently, all patients with tumors currently undergo MRI. The most recent 37 
patients underwent MRI as the primary investigation; before this, the patients 
routinely had a CT scan. The tumors were all macroadenomas, with an average size of 
258mm3. The MRI findings were tumor alone in 12 patients, mixed hemorrhage and 
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Figure 2.2: (a) MRI scan of a 44 year old man who presented with headache and 
diplopia showing a large pituitary adenoma that is compressing the optic chiasm and 
shows evidence of hemorrhage and necrosis. (b) MRI scans 3 months after a 








2.3.3 Endocrine findings 
 
Seventy-three percent of the patients (45 patients) had evidence of hypopituitarism, 
24% (15 patients) had normal function, and only 3% (2 patients) had hyperfunction. 
Thirty-nine of the patients had prolactin levels measured; of these, 63% had a result in 
the normal range, and only 4 patients had a level above 50ng/ml. The average 
prolactin level was 39ng/ml. Five patients had diabetes insipidus (DI), and 9 had 









  Hypofunction  Normal Hyperfunction  Unknown 
 
T4  34 (55%)  24 (39%) 0   4 (6%) 
 
Cortisol 38 (61%)  21 (34%) 0   3 (5%) 
 
GH  4 (6%)   16 (26%) 1 (2%)   41 (66%) 
 
Prolactin 1 (2%)   39 (63%) 7 (11%)  15 (24%) 
 
IGF1  2 (3%)   4 (6%)  0   56 (90%) 
 
G/T  25 (40%)  15 (24%) 0   22 (36%) 
 






Transsphenoidal surgery was undertaken in 77% of the patients (48 patients), 
craniotomy in 16% (10 patients), and 5% (3 patients) were managed conservatively. 
One patient died before any treatment. Most of the craniotomies were performed 
earlier in the series. The most common macroscopic finding at surgery was 
hemorrhagic necrosis in 47% of patients. Nineteen percent of patients (12 patients) 
were found to have infarcted tumor or necrotic material. Acute hemorrhage was found 
in 8% (5 patients) and old hemorrhage in 6% (10 patients). The macroscopic findings 
were not reported in 10% (6 patients) and 6% (4 patients) did not have surgical 
treatment (I patient died prior to any treatment and 3 managed conservatively). 
 
2.3.5 Conservative treatment 
 
Three patients were treated conservatively (Table 2). One of the patients had two 
previous pituitary operations and was awaiting radiotherapy for acromegaly, and the 
other two patients had no previous pituitary history. The diagnosis was made on the 
basis of the history, the typical findings of an apoplexy on imaging studies, and the 
subsequent course. None of these patients had visual loss, and all of them had partial 
opthalmoplegia. Two patients had suprasellar extension of the tumor, and one had 
predominant cavernous sinus involvement. One patient had prolactin levels of 
1200ng/ml, and one patient was a known acromegalic. All three patients were placed 
on hydrocortisone, and one patient was treated with bromocriptine. All had rapid 
resolution of symptoms, and the opthalmoplegias resolved within a few months. One  
patient remains on endocrine replacement therapy and bromocriptine. The other two 
have normal pituitary function. 
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  Patient 1  Patient 2  Patient 3 
 
Pituitary nil   acromegaly  nil 
history 
 
Visual  normal   normal   normal 
acuity 
 
Visual  normal   normal   unilateral 
fields        scatoma 
 
Cranial multiple  multiple  nil 
nerves 
 
MRI  suprasellar  cavernous sinus suprasellar 
  mixed haemorrhage- mixed haemorrhage mixed haemorrhage 
  &infarct  & infarct  & infarct 
 
Endocrine normal   acromegaly  hypopituitary 
        prolactinoma 
 
Management hydrocortisone hydrocortisone hydrocortisone 
 
Visual  normal   normal   normal 
outcome 
 
Replacement no   no   yes 
 
Radiotherapy no   yes   yes 
 
 
2.3.6 Pathological findings 
 
Forty-eight (77%) of the patients had clinically non-functioning pituitary adenomas, 1 
had a somatotropic adenoma (2%), 1 a prolactinoma, 1 an inflammatory lesion (2%), 
and in 8 patients (13%), the diagnosis was not confirmed histologically (this includes 
the 3 patients [5%] treated conservatively). The most common histological finding 
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was hemorrhagic infarction in 29 patients (47%), followed by infarction (or ghost 
cells) in 25 (40%), haemorrhage only in 5 (8%), and in the 3 patients (5%) treated 




The average length of follow-up in this series was 55.8 months (range, 1month-22 
years). The patients most recent clinical state at follow-up was assessed and divided 
into the following groups: alive, no symptoms, 37 patients (60%); alive with non-
disabling symptoms, 12 patients (19%); alive and disabled, 4 patients (6%); dead as a 
result off pituitary apoplexy, 3 patients (5%); and dead as a result of other causes, 6 
patients (10%) (Figure 30. 
Figure 2.3: Patients’ outcome in a series of 62 patients 
 
Visual acuity follow-up was available on 55 patients and was normal in 38 (69%), 
improved but not normal in 9 (16%), and unchanged in 2 (4%). None were worse, 














were normal in 38 patients (73%), improved but not normal in 11 (21%), unchanged 
in 2 (4%), and worse in 1 (2%). Cranial nerve function (54 patients followed up) was 
found to be normal in 43 patients (80%), improved but not normal in 11 (20%), and 
worse or unchanged in none. The visual outcomes are summarized in Table 3. 
 
Table 2.3: Outcome of visual and ocular nerve function of patients with  





 Normal        Improved,       Unchanged    Worse Blind 
             not normal 
 
Visual acuity 38   9  2  0 6  
(n=55)  (69%)  (16%)  (4%)   (11%)  
 
Visual fields 38  11  2  1 NA  
(n=52)  (73%)  (21%)  (4%)  (2%)   
 
CN palsies 43  11  0  0 NA  




Data on post-operative endocrine function were available on 58 patients. The 
majority, 48 patients (83%), required endocrine replacement. Three patients (5%) 
were hypopituitary but at follow-up were not on replacement, and 7 patients (12%) 
had normal pituitary function. DI was not present in 50 patients (86%), was transient 
in 3 (5%), and 5 patients (9%) were left with permanent DI. Post-operative 




The methodology of setting up a website using a common protocol and having two or 
more institutions entering patients, although not unique, is a very useful tool for 
collecting data. This allows for a wider experience not only in terms of numbers but 
also in the surgeons’ approaches to the clinical problems and assessment of 
complications of treatment and outcome. The website can be expanded and can be 
applied to answer other questions using the same principles. The data from the 
different participating centres can be scrutinized and differences between institutions 
and their results compared and analyzed. 
 
The definition of pituitary apoplexy has not always been uniform, with the most 
common factors being a characteristic clinical diagnosis associated with appropriate 
pathological features on histology. The majority of authors agree, however, that 
pituitary apoplexy is a clinical syndrome resulting from the haemorrhage, infarction 
or hemorrhagic infarction of a pituitary tumor that results in its sudden and fulminant 
expansion [Bills et al 1993, Bonicki et al 1993, Cardoso & Petersen 1984, Goel et al 
1995]. Apoplexy is of sudden onset and may be characterised by sudden headache, 
visual disturbance, opthalmoplegia, pituitary hypofunction, physical collapse, 
impaired level of consciousness, and death. All the patients in our series conformed to 
this definition of pituitary apoplexy. 
 
Pituitary apoplexy typically occurs in pituitary macroadenomas, which may be 
hyperfunctional or clinically non-functional tumors [Bills et al 1993, Randeva et al 
1999]. There is no subtype of adenoma that confers a higher risk of apoplexy [Biusse 
et al 2001]. Pituitary apoplexy has also been described in the normal pituitary gland, 
craniopharyngiomas, associated with lymphocytic hypophysitis, intrasellar teratoma, 
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and in Rathke’s cleft cysts [Bills et al 1993, Binning et al 2008, Brisman et al 1996. 
Dan et al 2002, Ebersold et al1983, Fernandez-Real et al 1995, Findling et al 1981, 
Lee & Pless 2003, Pawar et al 2002, Podgorski et al 1991, Reid et al 1985, Rolih & 
Ober 1993]. 
 
The majority of patients (81%) presenting with pituitary apoplexy in our study did not 
have a known pituitary tumor, and consequently making the correct diagnosis can be 
a challenge. Subarachnoid hemorrhage was the most common differential diagnosis in 
our series (65% of patients). Although subarachnoid hemorrhage can be a presenting 
feature of pituitary apoplexy, it is important to differentiate this condition from a 
subarachnoid hemorrhage from an intracranial aneurysm or vascular malformation 
[Cardoso & Petersen 1984, Ebersold et al 1983, Maccagnan et al, Sibal et al 2004, 
Wakai et al 1981]. In addition, aneurysms can be present in patients with pituitary 
tumors, and subarachnoid hemorrhage can be attributed to the aneurysm as well as 
pituitary apoplexy in previously described patients [Wakai et al 1981]. Errors in 
diagnosis are not uncommon, and the differential diagnosis can also include migraine, 
optic neuritis, stroke, myocardial infarction, encephalitis, sinusitis, cavernous sinus 
thrombosis and pituitary abscess [Ebersold et al 1983, Xenellis et al 2003]. 
 
Although the majority of cases of pituitary apoplexy are spontaneous, numerous 
precipitating factors have been suggested. Biousse et al [2001] reduced the multiple 
factors reported as precipitants of apoplexy into four categories: 1) reduced blood 
flow to the gland, 2) acute increase in blood flow in the pituitary gland, 3) stimulation 
of the pituitary gland, and 4) the anticoagulated state. Reduced blood flow may be 
associated with fluctuations in blood pressure, including hypotension often associated 
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with surgery, changes in intracranial pressure associated with head injuries, repetitive 
coughing, and procedures such as lumbar puncture, spinal anesthesia, myelography, 
and angiography, or after radiation, which may damage blood vessel integrity and 
impair blood supply [Biousse et al 2001, Cardoso & Petersen 1984, Holness et al 
1983, Randeva et al 1999, Wakai et al 1981]. Hemorrhagic infarction after partial 
removal of a large macroadenoma has been described, and it was postulated that the 
surgical removal of a considerable proportion of the tumors blood supply led to the 
apoplexy [Goel et al 1995]. One of our patients seems to have had a definite 
association with head injury, another followed cardiac surgery, and a third followed 
radiosurgery. Endocrine stimulation tests have been implicated in pituitary apoplexy, 
including administration of gonadotrophin-releasing hormone, thyrotropin-releasing 
hormone, and corticotrophin releasing hormone  [Biousse et al 2001, Matsuura et al 
2001, Randeva et al 1999, Rotman-Pikielny et al 2003, Sugita et al 1995]. The 
pathophysiological mechanisms are poorly understood, although it had been 
postulated that stimulation might abruptly increase the metabolic activity in these 
tumors, resulting in insufficient blood supply and thus precipitating apoplexy 
[Rotman-Pikielny 2003]. A similar mechanism may apply to stimulation with 
exogenous estrogens or during pregnancy [Biousse et al 2001, Cardoso & Petersen 
1984, Wakai et al 1981]. Bromocriptine therapy, both during and after withdrawal of 
therapy, has been associated with apoplexy [Biuosse et al 2001, Cardoso & Petersen 
1984, Goel et al 1995, Maccagnan et al 1995]. An anticoagulated state, whether 
iatrogenic from the administration of anticoagulant drugs or thrombolytic agents or 
pathological from thrombocytopenia, may also be associated with pituitary apoplexy 




The pathogenesis of the vascular event that results in the apoplexy is often poorly 
understood. Three main theories have been proposed in the literature; however, none 
fully explain the pathogenesis, and it may possibly vary in different tumors. A popular 
theory is that with rapid growth, the tumor outstrips its blood supply, resulting in 
ischemic necrosis and then hemorrhage [Cardoso & Petersen 1984, Ebersold et al 
1983, Goel et al 1995, Mohr & Hardy 1982, Randeva et al 1999, Schechter 1972]. 
Hemorrhage with and without apoplexy may, however, occur in small tumors 
[Cardoso & Petersen 1984, Randeva et al 1999]. It has been suggested that with tumor 
growth, the trabecular arteries arising from the superior hypophyseal artery may be 
compressed by the diaphragma sellae, resulting in ischemia and secondary necrosis of 
the tumor [Cardoso & Petersen 1984, Mohr & Hardy 1982, Onesti et al 1990, Rovitt 
& Fein 1972]. However, the inferior hypophyseal artery often is found 
angiographically to supply the adenoma; therefore, it is possible that ischemia initially 
begins in the normal gland rather than in the adenoma [Randeva et al 1999]. Cardoso 
& Petersen [1984] have postulated that an intrinsic vasculopathy in pituitary 
adenomas renders them more susceptible to infarction and hemorrhage. This may 
explain why pituitary adenomas are more susceptible to vascular injury than other 
tumors [Randeva et al 1999]. 
 
The manifestations of pituitary apoplexy can be variable, ranging from mild 
symptoms to a catastrophic presentation with permanent neurological deficit or even 
death [Milazzo et al 1996, Rolih & Ober 1993]. The clinical syndrome of pituitary 
apoplexy is usually of sudden onset, typically initially with headache, followed hours 
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or days later by other clinical manifestations. The clinical syndrome has usually fully 
evolved in a few hours to two days [Cardoso & Petersen].  
 
In this study, men (61%) were slightly more commonly affected than women, and the 
average age was 51 years, which is in agreement with other series [Cardoso & 
Petersen 1984]. Pituitary apoplexy in childhood is extremely rare [Sugita et al 1995].  
 
The clinical manifestations from a clinicopathological point of view have been 
divided into three groups: 1) destruction or compression of the pituitary resulting in 
hypopituitarism; 2) sudden enlargement upward or laterally, resulting in compression 
of neural structures; and 3) leakage of blood and necrotic tissue, resulting in 
meningism and symptoms similar to subarachnoid hemorrhage [Reid et al 1985]. 
 
In the current series, 84% of the patients presented with a sudden onset of headache. 
The cause of the headaches is not completely clear, although it is thought to be a 
result of pressure on the diaphragma sellae or meningeal irritation [Cardoso & 
Petersen 1984]. Eight patients had a diminished level of consciousness, and 3 were in 
coma. Sixty-one percent had impaired visual acuity, bitemporal hemianopia was 
present in 43%, and opthalmoplegia was found in 43%. These clinical features are 
similar to those previously reported [Bills et al 1993, Cardoso & Petersen 1984, De 
Villiers & Marus 1988, Ebersold et al 1983, Maccagnan et al 1995, MacFadzean et al 
1991, Milazzo et al 1996, Randeva et al 1999, Reid et al 1985, Rolih & Ober 1993]. 
Signs and symptoms from hypopituitarism are less frequent than headache and visual 
disorders and are usually detected by laboratory investigations, although 17 of the 
patients in the present series on history had some endocrine symptoms before the 
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apoplexy. The cure of syndromes associated with pituitary hypersecretion (e.g., 
acromegaly, hyperprolactinemia, and Cushing’s disease) after a pituitary apoplexy 
have been described [Findling et al 1981, Jones &Finer 1984, Kulah et al 1995]. 
 
MRI is undoubtedly the imaging tool of choice, because it clearly demonstrates the 
features of hemorrhage and infarction, the suprasellar extension, compression of the 
chiasm, and extension into the cavernous sinuses [Bills et al1993, Dubuisson et al 
2006, Milazzo et al 1996, Onesti et al 1990, Ostrov et al 1989, Piotin et al 1999]. A 
CT scan is also helpful if MRI is unavailable or is contra-indicated [Chanson et al 
2004, Laws & Ebersold 1982, Onesti et al 1990, Ostrov et al1995, Post et al 1980, 
Wakai et al 1981, Weisberg 1977]. As an initial emergency room investigation, a 
lateral cranial x-ray may show an enlarged sella in a patient with suspected apoplexy 
[Cardoso & Petersen 1984, Fitz-Patrick et al 1980]. Cerebral angiography is 
sometimes used to exclude a cerebral aneurysm, but MRI and Magnetic Resonance 
Angiography are as effective and safer. 
 
The two pillars of management of pituitary apoplexy have been transsphenoidal 
decompression and immediate institution of high dose corticosteroid replacement 
therapy [Bills et al 1993, Brisman et al 1996, Cardoso & Petersen 1984, Laws & 
Ebersold 1982, Sibal et al 2004]. There is consensus that high-dose corticosteroid 
replacement therapy and careful management of fluid and electrolyte balance is 
mandatory; however, there is some disagreement with regard to surgical treatment 
[Ayuk et al 2004, Brisman et al 1993, Cardoso & Petersen 1984, Chanson et al 2004, 
Gruber at al 2006, Reid et al 1985, Zhang et al 2007]. Randeva et al [1999] strongly 
advocate early transsphenoidal surgery for pituitary apoplexy, with particular urgency 
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in patients with deteriorating vision. They argue that the procedure has a low 
morbidity and mortality and that they reliably reversed or improved the neuro-
opthalmological deficits and furthermore noted that the improvement was more likely 
on those patients operated on within 8 days (73%) compared with those operated on 
later (42%). De Motta et al [1999] reported a higher mortality rate when the patients 
were not treated surgically. Bills et al [1993] analyzed retrospectively a series of 38 
patients and concluded that there was significantly improved outcome of visual acuity 
and a similar trend in visual field improvement in patients operated on in the first 
week. They therefore thought that early but not necessarily emergency surgery 
resulted in better visual outcome. The exception was in patients in whom sudden 
severe loss of vision occurred, and it was thought that emergency surgery was 
required in these patients. In patients who present with blindness, some authors have 
described improvement, whereas other reported no effect from surgery [Agrawal & 
Mahapatra 2005, Bills et al 1993, Onesti et al 1990]. Even late surgery for pituitary 
apoplexy is described as having satisfactory results in improved visual function [Bills 
et al 1993, Epstein et al 1971, Peter & Tribolet 1995, Randeva et al 1999]. Some 
authors have also described a lower incidence of hypopituitarism in patients treated 
surgically [Chuang et al 2007, Onesti et al 1990, Randeva et al 1999]. The lack of 
predictability of the clinical course of pituitary apoplexy after the initial ictus has been 
cited as an indication for early surgery [Brisman et al 1996]. Craniotomy is used very 
rarely and only when there is a contraindication to transsphenoidal surgery. 
Stereotactic surgery may have a role in patients who are medically unfit for a more 
invasive procedure [Onesti et al 1990]. The successful use of endoscopic techniques 
for pituitary surgery will certainly extend to the treatment of pituitary apoplexy 
[Cappabianca et al 2002]. 
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Maccagnan et al [1995], in a prospective study in which all patients were initially 
treated with high-dose dexamethasone and in whom surgery was performed only if 
there was no improvement in the first week, concluded that patients with visual 
impairment or a diminished level of consciousness would benefit from surgery, but in 
those presenting with opthalmoplegia, conservative treatment was just as effective. 
Improvement of ocular paresis has been well described with surgery, but conservative 
treatment has also been successful [Bills et al 1993, Brisman et al 1996, Maccagnan et 
al 1995, Onesti et al 1990, Randeva et al 1990, Seyer et al 1992]. Sibal et al [2005] in 
their retrospective review of forty-five patients with pituitary apoplexy concluded that 
those patients without neuro-opthalmic signs or who exhibited mild and non-
progressive signs could be managed conservatively in the acute stage. Ayuk and co-
workers, in their retrospective analysis of 33 patients with pituitary apoplexy, found 
that 54% of them were treated conservatively. They concluded that patients 
presenting acutely with pituitary apoplexy in whom there was no evidence of visual 
deficit or where there was evidence of spontaneously resolving deficit, could be 
treated conservatively without any deleterious effect on vision or endocrine outcome 
[Ayuk et al 2004]. Gruber et al [2006] found no apparent difference in visual outcome 
between those patients managed surgically and those managed conservatively; they 
found that apart from blindness, nearly all visual defects improved significantly or 
resolved completely in both conservatively and surgically managed patients over 
long-term follow-up. In our series three patients were successfully treated 
conservatively. Two of the patients were already showing signs of improvement of 
the headaches and opthalmoplegia at the time of presentation. The third patient was 
found to have a markedly elevated prolactin level and hyponatremia and responded 
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very well to bromocriptine, hydrocortisone and electrolyte correction. Two of the 
patients had entirely normal vision, and the third had a minimal visual field defect and 
normal acuity. Bromocriptine use in prolactinoma patients who have had apoplexy is 
well described [Brisman et al 1996]. 
 
Although there is varying opinion among different authors, a reasonable guideline for 
surgical treatment of pituitary apoplexy is outlined below. Surgery is indicated if there 
is a diminished level of consciousness, hypothalamic disturbance, or visual 
impairment. Emergency surgery is required when there is deteriorating vision, sudden 
onset of blindness, or diminished level of consciousness. Early surgery within the first 
week is recommended with visual impairment. If the patient is examined sometime 
after the ictus (days or weeks) and shows a stable or improving opthalmoplegia, then 
conservative treatment is justified. The most difficult decision involves 
opthalmoplegia, and although we would advocate surgery in the early presentation, 
conservative management can be justified, particularly if there is an isolated ocular 
palsy. 
 
There has been a marked improvement in outcome in pituitary apoplexy over the past 
30 years that reflects the progress of surgical and endocrine management. The visual 
outcome is related to length of history, severity of the initial visual defect, the 
appearance of the optic disc, and early decompression [Bills et al 1993, Esasser et al 
2005, McFadzean et al 1991, Parent 1990, Peter & de Tribolet 1995, Randeva et al 
1999]. In our series there was an improvement in visual acuity of 76% and of visual 
fields of 79%, which is similar to other series [McFadzean et al 1996, Peter & de 
Tribolet 1995, Randeva et al 1999]. Ocular paresis whether treated conservatively or 
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with transsphenoidal decompression, has a good prognosis, with normalization or 
improvement in up to 91% [Bills et al 1993, Kim et al 2007, McFadzean et al 1996, 
Seyer et al 1992, Tanriverdi et al 2007]. Seventy-seven percent of patients in the 
present series required endocrine replacement therapy, usually thyroid or cortisol 
replacement, which is similar to other published series [Bills et al 1993, Dubuisson et 
al 2006, Ebersold et al 1983, Fernandez-Real 1991, Laws & Ebersold 1982, Lubina et 
al 2005, Vidal et al 1992]. DI is much less common, probably because the blood 
supply of the posterior pituitary is different from that of the anterior [Bills et l 1993]. 
We found transient DI in 5% of patients and permanent DI in 8%. The overall 
outcome was good, with 60% of patients alive with no symptoms and 19% alive with 
minor non-disabling symptoms. Only 6% of patients were severely disabled and 5% 




Pituitary apoplexy is a rare but potentially life-threatening condition. The diagnosis is 
easily missed, because in the majority of patients, the pituitary adenoma is 
undiagnosed, and clinically, the picture can be mistaken for subarachnoid hemorrhage 
or meningitis. The majority are spontaneous, although a number of precipitating 
factors have been implicated. The diagnosis therefore rests on a high suspicion in 
patients presenting with headache, visual acuity and field abnormalities, ocular 
muscle palsies, diminished level of consciousness, or hypothalamic disturbance. An 
MRI scan is the imaging procedure of choice. High-dose corticosteroid replacement 
should be given to all patients. Emergency transsphenoidal decompression should be 
performed in patients with a diminished level of consciousness, hypothalamic 
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disturbance, and sudden severe visual disturbance or blindness. In patients with mild 
or moderate visual impairment, the surgery should be performed as soon as possible 
within the first week. There is evidence that isolated cranial nerve palsies may be 
successfully managed conservatively, as may patients who present long after the ictus 
















PITUITARY APOPLEXY: DO HISTOLOGICAL 
FEATURES INFLUENCE THE CLINICAL 




In the majority of published series, no differentiation is made between pure infarction 
and hemorrhage with or without infarction, and very few cases of pituitary apoplexy 
due to pure infarction have therefore been described. As most cases of pituitary 
apoplexy are associated with hemorrhage, cases due to infarction have been included 
in series with hemorrhagic cases, with no distinction being made between the two. 
However, a small number of cases of pure infarction have been previously described 
by Brougham et al [1950], Ebersold et al [1983], Gurling [1955], Mohr & Hardy 
[1982], and Rovit &Fein [1972]. De Villiers and Marus [1988], after 
histopathological examination of resected tumors, described five cases of infarction 
with no hemorrhage, in their series of 15 patients with pituitary apoplexy. Chako et al 
[2002] found that 15 of the 41 patients with pituitary apoplexy included in their series 
had infarction alone on histopathological examination. 
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In this study, which combines the experience of two neurosurgical centers, we 
compare the patients with pituitary apoplexy who were found on histological 
examination to have pure infarction with those who had hemorrhage or hemorrhagic 
infarction of a pituitary tumor. Particular attention was paid to clinical presentation 
and outcome. 
 
3.2 Clinical material and methods 
 
A retrospective series of 62 patients with pituitary apoplexy treated at Groote Schuur 
Hospital (GSH), University of Cape Town, South Africa, and University of Virginia 
Health System (UVA), Charlottesville, Virginia, USA, was collated. Thirty-eight 
consecutive patients were treated by two surgeons at GSH between 1972 and 2003, 
and 24 were treated by a single surgeon at UVA between 1992 and 2003. Fifty-eight 
patients were surgically treated, one patient died pre-operatively but underwent a 
post-mortem examination, and three patients were treated conservatively. 
 
For the purposes of this study, the histopathological reports from the pathology 
departments of both institutions were used to divide the patients into two groups: 
those in whom the histological finding was infarction (or ghost cells), and those in 
whom only hemorrhage or hemorrhagic infarction was encountered. The three 
patients who were treated conservatively had no histological confirmation of the 
pathological entity and were therefore excluded from the study. In the patient who 
died pre-operatively, however, a histological examination of the pituitary tumor found 
at post-mortem was performed and this individual could therefore be included. 
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Fifty-nine patients (mean age 51.1 years) were entered in the study. The mean 
duration of follow-up was 55 months (range 1 month – 22 years). Forty-eight patients 
had clinically non-functional pituitary adenomas, one each had a somatotroph 
adenoma, a prolactinoma, and an inflammatory lesion, and in eight a pituitary 
adenoma or other underlying disease was assumed, but could not be confirmed 
because the tissue studied was necrotic and / or hemorrhagic. Histopathological 
examination of the pituitary lesion underlying the pituitary apoplexy was performed 
in 59 patients, who could therefore be included in the retrospective analysis. Our 
standard procedure was to collect the entire pathological specimen for histological 
examination to improve the accuracy of the diagnosis. Twenty-two patients (37%) 
had infarction alone on histopathological examination (Figure 3.1) and 37 (63%) had 
hemorrhagic infarction or hemorrhage (Figure 3.2). In Figure 3.3, photomicrographs 
of specimens obtained in the two major histopathological types are contrasted. 
Twenty-two patients were found to have infarction alone, hemorrhage alone was 
present in five, and hemorrhagic infarction in 32 patients on histological examination. 
The two groups were then compared with regard to clinical presentation and outcome. 
Data were analyzed using Stata Version 10.0 (Stata Corporation, College Station, 
Texas, USA). Proportions were compared using Fisher’s exact tests and odds ratios 
with 95% confidence intervals (CI). Continuous variables were described as means 
and medians, and compared with Wilcoxon rank-sum tests. All statistical tests are 





Figure 3.1: Pituitary Infarction. Haematoxylin & Eosin staining at x200 
magnification. Shows outlines of homogeneous (and now non-nucleated/necrotic) 
neoplastic pituicytes consistent with an infarcted pituitary adenoma (the only 
surviving nuclei present being those in a few neutrophils (which probably represent 











Figure 3.2: Pituitary Haemorrhage. Haematoxylin & Eosin staining at x200 
magnification.  Shows (non-nucleated) red cells interspersed amongst homogeneous 














































Figure 3.3: Photomicrographs showing histopathological features of pituitary apoplexy. A 
and B: Extensive hemorrhagic infarction of a pituitary adenoma with complete replacement 
of the tumor mass by hemorrhage and necrosis. C and D: A large, infarcted corticotroph 
adenoma showing a focus of residual tumor cells in the centre of the section, surrounded by 
extensive necrotic tumor, which is more easily seen in panel D. H & E, original 






Details of patient distribution according to sex, age, and type of apoplexy are 





Table 3.1: Categorization of 59 patients with pituitary apoplexy 
 
 
          Patient Data 
                             
                                  Type of Apoplexy 
               INF                                              HNF 
          
          men 
       
               12 
                
                 22 
         
          women 
               
              10 
                
                 15 
         
          total 
              
              22 
                
                 32 / 5 * 
         
          mean age (years) 
             
              52.8 
                 
                 50.4 
 
 
HINF = hemorrhagic infarction / frank hemorrhage; INF = infarction alone. 







3.3.1 Presenting symptoms 
   
Although their presenting symptoms were similar, there was a marked difference between the 
two groups in the duration of symptoms before presentation at the neurosurgical departments. 
In patients with hemorrhage and / or infarction this was 10.9 days, which is half the time of 
patients in the group with infarction alone (20.1 days). The median duration of presenting 
symptoms was 4 days for patients with hemorrhage or  hemorrhagic infarction and 9 days for 
infarction alone. Comparison of the medians was p = 0.099 which approaches statistical 
significance. 
 
Headache was the most common presenting symptom in both groups; it was found in 18 
patients (82%) in the infarction and 31 (84%) in the hemorrhage  or haemorrhagic infarction 
group. Five patients with infarction alone (23%) reported mild visual impairment (acuity and 
/ or field defects) and none presented with non-functional vision or blindness. In the group 
with hemorrhage or hemorrhagic infarction, however, 19 patients (51%) presented with 
visual impairment, and 5 more (13.5%) presented with blindness. Individuals with visual 
impairment were more likely to to have hemorrhage or hemorrhagic infarction although this 
did not reach statistical significance (p = 0.054). Six patients (27%) from the infarction-only 
group experienced ptosis or diplopia, and eight (21.6%) in the hemorrhage or hemorrhagic 
infarction group presented with these symptoms. Two patients (5.4%) with hemorrhage or 
hemorrhagic infarction presented in a comatose state, while no patient with infarction alone 

























Figure 3.4: Clinical presentaton of patients in the infarction-only (INF)  and hemorrhage or 
hemorrhagic and infarction (HINF) groups. 
 
3.3.2 Clinical findings and endocrine status 
 
The level of consciousness (assessed according to the Glasgow Coma Sale) was diminished in 
one patient (5%) with infarction alone, but in the group with hemorrhage or hemorrhagic 
infarction this was the clinical finding in eight (21.6%) (p = 0.133). Visual function (visual 



































only mild visual impairment. There were no patients with non-functional vision or blindness in 
this group. In the patients with hemorrhage or hemorrhagic infarction, six (16.2%) had normal 
vision, 19 (51.4%) had impaired but functional vision, three (8%) had non-functional vision, 
and six (16.2%) were blind. Three could not be assessed because of coma. On statistical 
comparison significantly more patients with infarction alone were found to have nornal vision 
(p = 0.008), and significantly more patients with hemorrhage or hemorrhagic infarction had 
non – functional vision or were blind (p = <0.001).  Six patients (27%) with infarction alone 
were found to have an opthalmoplegia involving one or more cranial nerves, compared with 
eighteen patients (48.6%) with hemorrhage or hemorrhagic infarction. On endocrinological 
assessment, 17 patients (77%) with infarction alone showed evidence of hypopituitarism, four 
had normal pituitary function, and one had acromegaly. Thirty-one (83.8%) of the patients with 






































Figure 3.5: Clinical examination and endocrinological assessment in patients with infarction 
alone and in those who had hemorrhage or hemorraghic infarction. N Vision = normal vision, 
F Vision = functional vision, NF Vision = non-functional vision, LOC = diminished level of 















































 3.3.3. Clinical outcome 
 
The mean duration of the follow-up in this series was 55.8 months (range 1 month – 22 years). 
The outcome of the patients at follow-up examination was divided into the following 
categories: alive with no symptoms; alive with non-disabling symptoms (minor deficit); alive 
and disabled (major deficit); and dead due to the pituitary apoplexy or other causes (Figure 
3.6). Of the patients in the infarction only group, 17 (77%) were alive and well, four (18%) had 
minor disabilities, and none had major disabilities or had died (one patient was lost to follow-
up). Of the patients who were assigned to the hemorrhage or hemorrhagic infarction group, 15 
(37.8%) were well, 13 (35.1%) had minor disabilities, six (16.2%) had major disabilities, three 
(8.1%) died as a result of the pituitary apoplexy. Overall, poor outcomes were observed 



























Figure 3.6: Clinical outcome of patients in the two groups. Replace = hormone 
replacement therapy. 
 
Visual function was evaluated at follow-up review (Figure 3.7) and was regarded as 
normal if visual acuity was normal and the visual fields were full. Visual function was 
divided into normal, improved but not normal, not improved, worse or blind. In 
patients with infarction only, vision was normal at follow-up review in 21 (95%), and 
one patient (5%) was lost to follow-up. In the group with hemorrhage or hemorrhagic 
infarction, vision was normal in 17 patients (45.9%), improved but not normal in nine 
(24.3%), and seven (18.9%) remained blind. There was no patient in whom there was 
either no visual improvement, or worsening of vision, and in three patients assessment 

































infarction were likely to experience poor visual outcomes compared to patients with 
















Figure 3.7: Outcome of patients in the two groups in terms of visual function. Opth 
Residual = residual opthaolmoplegia. 
 
For assessment of opthalmoplegia at follow up, the patients were divided into those 
with no symptoms, those whose opthalmoplegia had improved but who had a residual 
deficit, and those with no improvement. In the infarction-only group, six patients were 
found to have opthalmoplegia at presentation. Of these, four were found to have no 









































residual deficit. In reviewing the entire infarction-only group, 19 patients (86%) had 
no opthalmoplegia at follow-up, two (9%) had a residual deficit, and one (5%) was 
lost to follow-up. In the goup with hemorrhage or hemorrhagic infarction, 18 patients  
had opthalmoplegia at presentation. In 11 of these patients, the opthalmoplegia had 
completely resolved at follow-up evaluation, and in seven, it had improved. In 
reviewing the hemorrhage or hemorrhagic infarction group as a whole, 22 patients 
(59.5%) had no evidence of opthalmoplegia at follow-up, seven (18.9%) had 
improved, and one (2.7%) had shown no improvement. Three patients died before 
they could be assessed. Resolution of opthalmoplegia was more common in infarction 
alone compared to hemorrhage or hemorrhagic infarction, and this difference 
approached statistical significance (p = 0.054). Eighteen (82%) of the 22 patients in 
the infarction group required long-term hormone replacement therapy for 
hypopituitarism, three (13%) had normal pituitary function, and in one case (5%) the 
pituitary status was unkown because the patients were lost to follow-up. Thirty-two 
(86.5%) of the thirty-seven patients in the group with hemorrhage or hemorrhagic 
infarction required endocrine replacement therapy. Of the five remaining patients, 
three did not survive (they died in the acute phase of the apoplectic episode) and the 











We assessed 59 patients with pituitary apoplexy to see if there were differences in 
clinical presentation and outcome when patients were divided based on the 
histopathological findings of infarction alone or hemorrhage and hemorrhagic 
infarction. Histopathological differentiation was chosen because this is the most 
reliable method of distinguishing between the two groups. Although MRI is currently 
the most effective neuroimaging method for diagnosing pituitary apoplexy, Kurihara 
et al [1998] found that 12 of the 14 cysts judged pre-operatively as nonhemorrhagic in 
fact contained hemorrhagic components. Piotin et al [1999], in their series in which 
MRI  studies were obtained in 11 patients with pituitary apoplexy, concluded that this 
disease may present with varying MRI features, including nonhemorrhagic and 
hemorrhagic changes on T1-weighted images. It is well described that the MRI 
features of the blood components in a hemorrhage change over time. Acute 
hemorrhage may therefore may not be demonstrated unless the correct sequences are 
used, and furthermore, the imaging characteristics of the blood in a hemorrhage 
change between the acute and the subacute stages [Lacallee et al 1995, Piotin et al 
1999]. Consequently it is possible to miss a hemorrhage in the acute stage, and unless 
follow-up MRI studies are performed to allow the changed characteristics of the 
hemoglobin degradation products to be recognised, the differentiation between 
hemorrhage and infarction may not always be clear. 
 
On CT scans the density of the blood changes as it degenerates, thus making it 
difficult to distinguish between hemorrhage and infarction, and acute hemorrhage 
found at operation is not always visible on the pre-operative scan [Post et al 1980]. It 
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must be noted, however, that an error could result if only a small surgical specimen is 
sent for histopathological examination; that particular fragment may not necessarily 
represent the findings throughout the tumor. Therefore, it is important to collect the 
entire specimen, if possible, for histological examination. Although sometimes it may 
be difficult to distinguish between pure infarction and hemorrhage or hemorrhagic 
infarction on histological examination, it is not impossible, because in the majority of 
cases the histological appearance is easily distinguishable. 
 
The clinical presentation of pituitary apoplexy varies from a clinically relatively 
benign event to a catastrophic episode with severe neurological deficit, endocrine 
failure, or even death [Rolih & Ober 1993]. When we compared the clinical 
presentations and findings in patients in our series, we found a difference between 
individuals who had histological evidence of infarction only, compared with those 
who had hemorrhage or hemorrhagic infarction only. The interval between onset of 
symptoms and presentation at the neurosurgical department was twice as long in those 
who had infarction alone (20.1 days), compared with those who had hemorrhage or 
hemorrhagic infarction (10.9 days), while the median duration was 9 and 4 days 
respectively. In both groups of patients, the most common presenting symptom was 
headache, but the visual symptoms were more common and of greater severity in the 
hemorrhage or hemorrhagic infarction group than in the infarction-only group. 
Twenty-two percent of the patients with infarction had relatively mild visual 
symptoms, retaining functional vision. In contrast, in the group of patients with 
hemorrhage or hemorrhagic infarction, visual symptoms occurred in 64.5% and were 
more severe; 13.5% presented with blindness. Patients with visual impairment were 
more likely to have hemorrhage or hemorrhagic infarction (p = 0.054). Diplopia was 
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equally common in both groups. Two patients in the group with hemorrhage or 
hemorrhagic infarction presented in a comatose state. 
 
Clinical findings were similar, with an increase in the number and severity of 
neurological deficits in patients with hemorrhage or hemorrhagic infarction. The 
visual findings in the patients with infarction were normal in 50%, and mild deficits 
of functional vision were present in the remaining 50%. In contrast, in the group of 
patients with hemorrhage or hemorrhagic infarction, normal vision was present in 
only 16.2%, whereas 52.3% had diminished but still functional vision, 8.1% had 
nonfunctional vision, and 16.2% were blind (vision could not be assessed in 8%). 
Significantly more patients with infarction alone had normal vision (p = 0,008), while 
patients with hemorrhage or hemorrhagic infarction were more likely to have non-
functional vision or blindness (p = <0.001). Opthalmoplegia was also a more common 
finding in the patients with hemorrhage or hemorrhagic infarction. Only 5% of 
patients with infarction alone had a diminished level of consciousness (GCS less than 
15), compared to 22.2% in the group with hemorrhage or hemorrhagic infarction. This 
is in agreement with the findings if De Villiers and Marus [1988]. From the difference 
in time to presentation we may infer that the symptoms in the group of patients with 
infarction alone were less severe and not as catastrophic, resulting in a longer interval 
elapsing before they sought medical help. Chacko and coworkers [2002] described a 
longer symptomatic interval in patients who were found to have pale necrotic tissue 
with no evidence of hemorrhage at surgery. They ascribe this to the resorption of 
blood products, however, in my view these patients had pure infarction with no 
hemorrhage, because blood breakdown products would have been present if 
hemorrhage had also occurred. 
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The pathogenesis of events that lead to infarction, hemorrhage, or a combination of 
the two are poorly understood, and a number of theories have been proposed (see 
Chapter 2). In the case of hemorrhage, it is not always possible to determine if the 
primary event was infarction followed by hemorrhage or if the primary event was the 
hemorrhage itself. 
 
The fact that the patients with infarction alone appear to have a more benign 
presentation than those with hemorrhage or hemorrhagic infarction supports the 
suggestion that the expansion of the tumor and compression of the surrounding 
structures is not as severe in pure infarction as in the latter condition. The infarction 
may raise the pressure in the tumor, but possibly not as rapidly or severely as in a 
hemorrhage or hemorrhagic infarction, so that tumor expansion is less marked and 
compression of the surrounding structures is consequently less severe. 
 
Patients in our series who had infarction alone had a better outcome than those with 
hemorrhage or hemorrhagic infarction. The patients in the group with infarction were 
normal neurologically in 77% of cases, compared with 37.8% of patients in the group 
with hemorrhage or hemorrhagic infarction. The remainder of the group with 
infarction alone only had minor neurological deficits (5% were lost to follow-up). 
This was in contrast to the patients with hemorrhage or hemorrhagic infarction, in 
whom 35.1% had a minor neurological deficit, 16.2% a major one,  and in whom 8% 
died as a direct result of the apoplexy (five died of other unrelated causes). Overall, 
poor outcomes were signicantly more common in patients with hemorrhage or 
hemorrhagic infarction (p = 0.013). Visual function, when assessed as an independent 
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factor, also proved to have a much better outcome in the patients with infarction 
alone. In this group, vision at follow-up was normal in 95%. In the patients with 
hemorrhage or hemorrhagic infarction, however, vision was normal in only 45.9%, it 
had shown improvement but was not normal in 24.3%, and 18.9% of the patients in 
this group had remained blind (the three deaths were excluded). Patients with 
hemorrhage or hemorrhagic infarction were more likely to have a poor visual 
outcome (p = <0.001) There was also a greater improvement in the opthalmoplegia of 
the patients with infarction alone. 
 
Similar numbers of patients from both groups required hormone replacement therapy 
for hypopituitarism, indicating that the degree of destruction of normal pituitary tissue 
was comparable. The origin of the hypopituitarism may be due to compression or 
destruction of the pituitary gland, interruption of the blood supply to the gland, or 
pituitary stalk damage. This may present in varying degrees in both groups, resulting 
in hypopituitarism. Nevertheless, the worst outcome may again be related to the 
severity of the initial ictus, in which there may be greater pressure from hemorrhage 
or hemorrhagic infarction than from infarction alone within the adenoma, resulting in 
more severe and rapid expansion of the tumor, leading to more severe injury to 
surrounding structures. The blood may also escape from the confines of the tumor 
capsule, resulting in clinical features similar to subarachnoid hemorrhage. 
 
The fact that pure infarction-related apoplexy seems to have a less catastrophic course 
than apoplexy due to hemorrhage or hemorrhagic infarction may have some 
implications for the management of pituitary apoplexy. The endocrine replacement 





Pituitary apoplexy remains a potentially life-threatening disease. Its presentation, 
however, may vary from that of a relatively benign illness to major neurological 
deficits and even death. Consequently, its early recognition and treament are vital. 
Histopathologically the findings may be infarction, hemorrhagic infarction, or 
hemorrhage alone. Patients who present with pituitary apoplexy due to infarction 
alone in a pituitary adenoma have a more benign illness with a less severe 
presentation and better outcome than those in whom histological studies show 


















The aim of this study was to review the operative findings, histopathological reports 
and MRI scans on consecutive patients to assess if the histopathology found at 
surgery could be reliably predicted on the MRI scan pre-operatively. If one were able 
to correlate the histological findings with those found on MRI then we may get an 
improved understanding of the presentation and may be able to better predict the 
outcome of these patients pre-operatively. 
 
4.2. Clinical material and methods 
 
Thirty-eight patients were treated for pituitary apoplexy in the Department of 
Neurological Surgery, University of Virginia, Charlottesville, Virginia, USA from 
January 1996 to March 2006. Two surgeons carried out transsphenoidal surgery, 
either microscopic or endoscopic on these patients. The operative specimens were 
characterized by the Department of Neuropathology, University of Virginia into two 
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separate groups: those in whom the histological findings were of infarction with no 
evidence of hemorrhage and; the second group which was characterized hemorrhagic 
infarction or hemorrhage alone. The entire mass of removed pituitary tumor was sent 
as the specimen for histological study. 
 
Thirty-six of the patients had pre-operative MRI scans and in 2 patients CT scans 
were the only pre-operative imaging. One patient was unable to have an MRI scan as 
he had a cardiac pacemaker. The other had a CT scan done in a foreign country and 
was transferred to Charlottesville as an emergency, therefore the CT scan was 
assessed as being diagnostic and no further imaging was thought necessary prior to 
emergency surgery. The two patients who only had CT scans and no MRI study were 
excluded from the study. The MRI scans were collected and reviewed. When the 
scans were no longer available the radiologists report alone was reviewed. The MRI 
images as well as the radiologists’ report were studied in 19 patients and in 17 
patients the radiologists’ report alone was documented. The features that were noted 
in particular were: the presence of blood products indicating hemorrhage or 
hemorrhagic infarction, appearance of infarction alone with no blood products, the 
presence of pituitary tumor alone with no obvious evidence of pituitary apoplexy and 
the presence of mucosal thickening in the sphenoid sinus. 
 
The MRI scan findings on 36 patients were divided into 3 groups. The first group was 
those in whom imaging features were in keeping with infarction alone. Typically this 
group showed no hemorrhage on T1 or T2 sequences, and no enhancement with 
gadolinium except for characteristic rim or capsule enhancement (Figure 4.1). The 
timing of the MRI scan was also taken into consideration when looking for blood 
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breakdown products. The second group showed evidence of hemorrhage with or 
without infarction on T1 and T2 sequences (Figure 4.2). The third group clearly 
showed a pituitary tumor, but there was no evidence of hemorrhage or infarction and 








Figure 4.1: T1 sequence of MRI in axial and sagittal plane with contrast. There is 
enhancement of the capsule with low intensity signal within the tumor. This picture 
may suggest infarction of the tumor, but hemorrhage, depending on the timing of the 









        
 
Figure 4.2: Coronal MRI T1 sequence without contrast (Left scan) and with contrast (Right 
scan). The high intensity signal on the uncontrasted scan suggests the presence of blood 
products. On the contrasted scan the low intensity signal may represent infarcted areas that 
are mixed with the blood products suggesting the picture of hemorrhagic infarction, which 
was confirmed on histopathological studies. 
 
The MRI scans were reviewed separately from the histopathological reports in a blinded 
fashion. The results from the histological groups were then retrospectively compared with 
the MRI findings to see if accurate prediction of infarction alone or hemorrhage or 
hemorrhage infarction on the MRI scan was possible. In addition the histological groups 
were compared with regard to severity of presenting symptoms and outcome in this series 
of patients. Data were analyzed using Stata Version 10.0 (Stata Corporation, College 
Station, Texas, USA). Proportions were compared using Fisher’s exact tests and odds ratios 
with 95% confidence intervals (CI). Continuous variables were described as means and 
medians, and compared with Wilcoxon rank-sum tests. All statistical tests are two-sided at 





The mean age of the patients was 52.8 years with a range from 19 to 82 years, and 
there were 20 men and 16 women. The average length of time from onset of 
symptoms until presentation at the department of Neurosurgery, University of 
Virginia, or the referring physician was 14.8 days with a range of 1 day to more than 
90 days. Four patients had a previous history of pituitary adenoma: two patients had 
been treated conservatively, one had Nelson’s syndrome, and one had previous 
surgery for a pituitary adenoma.  
 
The histopathological findings were in keeping with a pituitary adenoma, which had 
undergone apoplexy in 35 patients, and in 1 patient there had been a hemorrhage into 
a Rathke’s cleft cyst. For the purposes of this study the histopathological findings 
were divided into two groups. The first group included patients in whom only 
infarction could be identified on histopathological examination (ghost cells) with no 
evidence of hemorrhage. The second group consisted of patients in whom the 
histopathological sections showed hemorrhagic infarction or hemorrhage alone. The 
routine practice is to send the entire removed apoplectic tumor for histology 
examination, and in this way we try to prevent small specimens only representing part 
of the tumor from being incorrectly classified. 
 
4.3.1 MRI vs. histopathology and intra-operative findings 
 
Thirty-six patients had MRI scans that could be compared to the histopathology. 
Fifteen patients had MRI features consistent with hemorrhagic infarction or 
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hemorrhage alone; in 17 patients only infarction of the pituitary tumor was evident 
and in 4 patients only a pituitary tumor was demonstrated with no imaging evidence 
of hemorrhage or infarction. 
 
The MRI diagnosis of hemorrhagic infarction or hemorrhage alone was then 
compared to the surgeon’s observations intra-operatively. In 14 of the patients the 
intra-operative observations of the surgeon were hemorrhagic infarction or 
hemorrhage; in only one case did the surgeon think that infarction alone was present. 
Therefore the MRI findings of hemorrhagic infarction or hemorrhage correlated in 14 
out of 15 patients (93%) with surgical observations (95% CI: 68-99%). When the 
MRI diagnosis of hemorrhagic infarction or hemorrhage was compared with the 
histopathological slides, 13 patients had the typical findings of hemorrhagic infarction 
or hemorrhage and only 2 of those had infarction alone: the MRI scan findings 
correlated in 13 of 15 patients (86%) with the histopathology (95% CI: 60-98%)   













Figure 4.3: MRI scan vs. histopathology. HINF = hemorrhagic infarction or 
hemorrhage on histopathology, INF = infarction alone on histopathology. MRI-HNF 
= hemorrhagic infarction or hemorrhage on MRI scan, MRI-TUM = tumor alone on 
MRI scan, MRI-INF = infarction alone on MRI scan 
 
The MRI scan diagnosis of infarction, when compared to the surgeon’s intra-
operative observations was accurate in 16 patients (94%) (95% CI: 71-100%), 
matched the histopathology in 15 of 17 patients (88%) (95% CI: 64-99%), and were 
found to be hemorrhagic infarction or hemorrhage in only 2 (11%).  There were 4 
patients with the diagnosis of a pituitary tumor alone on MRI scan. In two patients the 
surgeon thought the findings were consistent with infarction and in 2 hemorrhagic 
infarction or hemorrhage, while the histopathology in 3 patients demonstrated 
hemorrhagic infarction or hemorrhage, and in 1 infarction alone. 
 
In the 19 patients where the actual MRI scans and reports were reviewed, it was felt 














There was possible subtle mucosal thickening in 4 patients and no mucosal thickening 
in two. 
 
4.3.2. Histopathology vs. MRI 
 
The histopathological studies on the 36 patients demonstrated infarction-alone with 
no evidence of hemorrhage in 17 patients and hemorrhagic infarction or hemorrhage 
alone in 19 (hemorrhagic infarction was present in 17 patients and hemorrhage alone 
in 2). The histopathological diagnosis was then compared to the MRI scan findings 
(Figure 4.4). 
Figure 4.4: Histopathology vs. MRI scan. HISTO-INF = infarction alone on 
histopathology, HIISTO-HINF = hemorrhagic infarction or hemorrhage on 
histopathology, MRI-HINH  = hemorrhagic infarction on MRI scan, MRI-TUM = 
tumor alone on MRI scan, MRI-INF  = infarction alone on MRI scan. 
 
The nineteen patients who were in the histopathological grouping of hemorrhagic 















hemorrhagic infarction or hemorrhage in 13 patients (68%), pituitary tumor in 3 
(16%), and infarction alone in 3 (16%). Therefore in 68% of cases the histopathology 
correlated with what had been demonstrated on MRI scan (95% CI: 43-87%). 
 
Of the 17 patients with a histopathological diagnosis of infarction alone, 14 (82%) 
were thought to only have evidence of infarction on MRI scan, two (12%) 
hemorrhagic infarction or hemorrhage and one (6%) a pituitary tumor only. Therefore 
the histopathological correlated with the MRI scan findings when viewed 
retrospectively in 82% of patients (95% CI: 57-96%). 
 
4.3.3. Histopathology vs. clinical presentation 
 
The seventeen patients in whom the histopathology was infarction alone presented 
with headache in 14 cases, visual impairment in 8 - although none were blind and all 
had functional vision – and diplopia in 2 patients. One patient presented with a history 
of a diminished level of consciousness, and 1 had Cushing’s disease. The nineteen 
patients with hemorrhagic infarction or hemorrhage alone presented with headaches 
in 17, diminished vision in 7 (including 2 with blindness), two with diplopia, and 2 
with a diminished level of consciousness.  
 
The mean duration of symptoms was 12.4 days for the infarction group, and 15.4 days 
for the patients who had hemorrhage or hemorrhagic infarction. However, these mean 
values may be misleading, as in the case of the patient with Cushing’s disease who 
was found to have infarction of a pituitary macroadenoma, had mild symptoms of 
visual impairment for a year with no abrupt headache or visual change suggestive of 
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an ictus, and therefore was not included in determining the mean value. In addition, a 
patient who was found to have hemorrhagic infarction on histology of a pituitary 
macroadenoma, had headaches for three months with no other symptoms.  
 
The time from the ictus to presentation was also divided into the first week following 
the ictus, the second week after the ictus, and more than 2 weeks following the ictus. 
In the first week following the ictus, nine patients in the infarction group, and 15 
patients in the hemorrhage or hemorrhagic infarction group presented to hospital. 
From day 8 to day 14 post-ictus, four patients in the infarction group and only 1 in the 
hemorrhage or hemorrhagic infarction group presented. Four patients in the infarction 
group, and 3 in the hemorrhage or hemorrhagic infarction group presented later than 2 
weeks following the ictus (Figure 4.5.). Therefore, 53% of patients in the infarction 
group presented within a week, compared to 79% of patients with hemorrhage or 
hemorrhagic infarction. Patients with infarction were 30% as likely to present in less 
than 1 week compared to those with hemorrhage or hemorrhagic infarction, but the 






Figure 4.5: Histopathology vs. time to presentation following ictus. HINF = 
hemorrhage or hemorrhagic infarction on histopathology, INF = infarction on 
histopathology. 
 
The clinical findings of both the patients with infarction only on histopathology and 
those with hemorrhage or hemorrhagic infarction are shown on Table 4.1. Only one of 
17 patients (6%) in the infarction group had a diminished level of consciousness at 
presentation, but 6 (32%) in the hemorrhage or hemorrhagic infarction group did (p = 
0.092). The visual findings are similar in both groups, except that 3 patients in the 
hemorrhage or hemorrhagic infarction group were blind, compared to none in the 
patients with infarction only. There was not a significant difference in visual findings 
between the two groups. Individuals with hemorrhage or hemorrhagic infarction were 
significantly more likely to have opthalmoplegia than those with infarction alone (p = 
0.010).  Therefore although the clinical findings were not markedly different between 














namely diminished level of consciousness and blindness in those patients with 
hemorrhagic infarction or hemorrhage on histopathology.  
 
Table 4.1: The histopathology related to the clinical presentation.  
 
GCS = Glasgow Coma Scale, N = normal, F = functional, NF = non functional, B = 
blind. 
 
4.3.4. Histopathology vs. outcome 
 
The mean length of follow-up was 29.4 months with a range from 1 week to 7 years. 
The outcome of these patients was divided into normal with no neurological deficits; 
minor deficit with very mild neurological impairment but easily able to function 
independently; major neurological deficit where the patient was not able to function 
independently; and dead. Eleven of the patients in the infarction group had a normal 
neurological outcome, five had minor deficits, and one a major deficit. Therefore 16 
of the patients (94%) in this group had a good outcome. In the hemorrhage or 
hemorrhagic infarction group, 13 patients had a normal outcome, 3 had minor deficits, 
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hemorrhagic infarction group therefore had a good outcome. There were no deaths in 
either group (Table 4.2). However, there was not a statistically significant difference 
between those patients with hemorrhage or hemorrhagic infarction and those with 
infarction alone (p=0.608). 
 
The visual outcome at follow-up in the infarction group was normal in 14 patients 
(82%), and there were improved minor visual deficits with functional vision in 3 
(18%). No patients were blind. In the hemorrhage or hemorrhagic infarction group of 
patients vision at follow-up was normal in 12 (63%), improved with functional vision 
in four (21%), and blind in 2 (11%). One patient was lost to follow-up early and was 
not re-assessed. The difference in visual outcome did not reach statistical significance. 
Fourteen of the patients in the infarction group had no opthalmoplegia at follow-up, 
and 3 still had residual deficits although they were improved. In the hemorrhage or 
hemorrhagic infarction group of patients 13 had no opthalmoplegia at follow-up, five 
were improved, and 1 patient was lost to follow-up and could not be assessed. 
Fourteen patients required replacement therapy in the infarction group, 16 in the 













Table 4.2: Histopathology compared to the outcome.  
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In Chapter 3 a series of 59 patients with pituitary apoplexy was divided on 
histopathological examination into two groups, namely infarction alone, or 
hemorrhage or hemorrhagic infarction, and the clinical presentation and outcome of 
these two groups of patients was described. The patients who presented with 
histological features of tumor infarction alone were found to have less severe clinical 
features on presentation, a longer history prior to presentation, and a better outcome 
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than those patients found to have hemorrhage or hemorrhagic infarction of the 
pituitary tumor. 
 
In the current series the histopathology studies were divided in a similar manner, and 
were compared to the MRI scans to ascertain if it is possible to correlate the imaging 
findings with the histopathological studies. 
 
MRI is more effective than CT scan in identifying the imaging features of pituitary 
apoplexy and is the investigation of choice [Bills et al 1993, Chanson et al 2004, 
Dubuisson et al 2006, Kyle et al 1990, Ostrov et al 1989, Randeva et al 1999]. Bills et 
al [1993] described the positive identification of a pituitary tumor in 94% of patients 
with pituitary apoplexy, but radiological features of hemorrhage or infarction were 
only noted in 46% on CT scan. CT scan cannot differentiate cystic or degenerative 
changes from old hemorrhage whereas MRI can [Ostrov et al 1984]. This is due to the 
increasing density of blood on CT scan as the blood degenerates making it impossible 
to differentiate radiologically subacute or chronic hemorrhage from other causes of 
low intensity signal such as degenerative changes or abscess. Similarly the low signal 
intensity with possible rim enhancement in a patient who has undergone infarctive 
pituitary apoplexy cannot be differentiated from degenerative changes, cysts, or even 
pituitary adenomas that have not undergone apoplexy that occasionally have rim 
enhancement [Post et al 1980]. In their series on pituitary apoplexy, Randeva et al 
[1999], found that CT scan revealed a pituitary tumor in 93%, and pituitary 
hemorrhage in 21%, whereas MRI identified pituitary tumor in 100% and hemorrhage 
in 88%. CT scan definitely is of benefit when there is no MRI scan available, but MRI 
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is far superior and should be the investigation of choice when possible. For this reason 
the two patients who only had CT scan in this series were excluded from the study. 
 
Pituitary apoplexy may present with different MRI features including hemorrhagic 
and non-hemorrhagic changes [Piotin et al 1999]. In hemorrhagic pituitary apoplexy 
in the acute phase (day 1-2) the appearance of hemorrhage is typically hyperintense 
on T1 images and hypointense on T2 images [Bonneville et al 2006, Lavallee et al 
1995, Riedl et al 2000, Tosaka et al 2007). The gadolinium enhanced images 
ordinarily do not provide additional information with regard to hemorrhage in the 
presence of blood, although when there is mixed hemorrhage and infarction there can 
be areas that are of low intensity that do not enhance [Piotin et al 1999, Riedl et al 
2000]. Signal intensity changes occur in sub-acute hemorrhage (day 3-15) due to the 
degradation of hemoglobin into methemaglobin, and the signal should appear bright 
on both T1 and T2 sequences [Glick & Tiesi 1990, Kyle et al 1990, Lavallee et al 
1995, Piotin et al 1999]. In the chronic phase (more than 15 days) the sedimentation 
of blood products may create a fluid level within the mass, a feature that is highly 
suggestive of hemorrhagic pituitary apoplexy [Bonneville et al 2006, Piotin et al 
1999]. In the case of apoplexy the evaluation of enhanced T1 images alone may be 
misleading because T1 weighted hyperintense blood products may be mistaken for 
contrast enhanced tumor [Riedl et al 2006]. Kurihara et al [1998] in a series of 15 
patients with hemorrhagic pituitary adenomas, found that the pre-operative finding of 
hemorrhage on the MRI sequences correlated well with their operative findings. 
Lazaro et al [1994] described 5 patients in whom pre-operative MRI showed evidence 
of intratumoral pituitary tumor hemorrhage, and in whom all 5 had operative 
verification of that hemorrhage. 
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Infarctive pituitary apoplexy alone has been described as low intensity on T1 and T2 
sequences with no contrast enhancement of the tumor, but with associated rim 
enhancement [Rogg et al 2002]. This appearance in the acute phase does not change 
in the subacute or chronic phase. Peripheral enhancement is not specific for infarctive 
pituitary apoplexy, and can also be seen in cystic pituitary adenomas and 
craniopharyngiomas. Diffusion weighted imaging may be useful in the diagnosis of 
infarctive pituitary apoplexy because it shows high signal intensity from restricted 
diffusion from infarction and can help to differentiate it from cystic macroadenomas 
and craniopharyngiomas [Bonneville et al 2006]. 
 
In our series the imaging findings on the pre-operative MRI were correlated with the 
findings at surgery. In the 15 patients who exhibited features of hemorrhagic 
infarction on MRI, fourteen were found to have evidence of hemorrhage at surgery 
(93%). The seventeen patients who were thought to have infarction alone on MRI 
matched the findings at surgery in 94%. The four patients in whom the MRI showed 
only tumor were found to have infarction alone in 2 cases and hemorrhagic infarction 
in two. Therefore, the correlation between our diagnosis on MRI and surgical findings 
were accurate in the majority of cases. The pre-operative MRI when compared to the 
histopathological examination was accurate in 87% of patients with hemorrhage or 
hemorrhagic infarction, and in 88% of patients where infarction alone was diagnosed 
on the pre-operative MRI. The pre-operative MRI therefore, is able to discriminate 
the infarction only and hemorrhage or hemorrhagic infarction groups of patients as 
determined at surgery and on histopathological examination in the majority of 
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patients. Although this sample size was relatively small, the precision around the 
estimates (as reflected by 95% CI) are reasonably precise. 
 
When we compared the histopathological diagnosis with pre-operative MRI findings 
the histopathology correlated with the MRI in 68% of patients with histopathological 
diagnosis of hemorrhage or hemorrhagic infarction, and in 82% of patients with 
infarction alone. The histopathological diagnosis could, therefore, be equated with the 
MRI findings in the majority of cases, although the findings were less accurate in 
hemorrhage or hemorrhagic infarction group. This is probably because the 
hemorrhage or hemorrhagic infarction group of patients had a more variable picture in 
that the appearance changed with time; therefore the likelihood of MRI findings being 
inaccurate was higher. 
 
Sphenoid sinus mucosal thickening described as a feature of pituitary apoplexy on 
MRI is thought to be a result of venous engorgement [Bonneville et al 2006]. Arita et 
al [2001] evaluated the MRI scans of 11 patients with a diagnosis of pituitary 
apoplexy in whom the MRI was done within 7 days of the ictus. In nine of these 
patients the sphenoid sinus mucosa was markedly thickened. In the four patients in 
this group who did not undergo surgery the mucosal thickening regressed 
spontaneously. In addition three patients who were imaged more than three months 
following their ictus had no mucosal thickening. Therefore it would appear that 
sphenoid sinus mucosal thickening is an acute manifestation of pituitary apoplexy that 
spontaneously resolves. In our series in 13 of the 19 patients (68%) in whom the MRI 
films could be studied for mucosal thickening, it was found to be present. Liu and 
Couldwell {2006] recently published their series on mucosal sinus thickening in 
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patients with pituitary apoplexy and found that it correlated with higher grades of 
pituitary apoplexy and poorer and neurological and endocrine outcomes. 
 
De Villiers and Marus [1988], and Chacko et al [2002] both described a group of 
patients in whom necrotic material only was found at surgery. De Villiers ascribed 
this to infarction of the pituitary tumor whereas Chacko thought it was essentially part 
of the resorption process of pituitary apoplexy.  
 
In the previous chapter (Chapter 3) the series of patients with pituitary apoplexy were 
divided on a histopathological basis into those that demonstrated infarction only and 
those with hemorrhage or hemorrhagic infarction (earlier series: 1970-2003). The 
patients with infarction only on histopathological examination tended to have a longer 
presentation history, less severe clinical signs, and a better outcome than those in 
whom hemorrhage or hemorrhagic infarction was demonstrated.  The results from the 
earlier series of patients in Chapter 3 have now been compared to the current series of 
patients (current series: 1996-2006). 
 
The time from the ictus to presentation in the earlier series of patients was almost 
double for the infarctive group of patients compared to those with hemorrhage or 
hemorrhagic infarction; however, in the current series there was no major difference 
in the mean calculated time. If, however, the patients were grouped into early (in the 
first week), and late (later than the first week), fifteen (79%) of the patients with 
hemorrhage or hemorrhagic infarction presented early and nine (53%) of the patients 
with infarction only presented early. Therefore, there is still a tendency for patients 
with hemorrhage or hemorrhagic infarction to present earlier than those with 
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infarction alone. In the current series of patients the differences in the severity of the 
clinical features in the two different histopathological groupings of patients was not as 
marked as in the earlier series, and do not reach statistical significance. However as 
the sample size is small in statistical terms there is a limitation in interpreting 
statistical significance (i.e. p values may not be definitive due to small sample size). 
However, the more severe clinical deficits, namely diminished level of consciousness, 
and blindness were more prevalent in the hemorrhage or hemorrhagic infarction group 
of patients. One out of 17 (6%) of the patients in the infarction group had a 
diminished level of consciousness compared to six out of 19 (32%) in the hemorrhage 
or hemorrhagic infarction group. In the earlier series 6% of the infarction group, and 
22% of the hemorrhage or hemorrhagic infarction group had a diminished level of 
consciousness. In the current series no patients were blind in the infarction group, but 
three (16%) were blind in the hemorrhage or hemorrhagic infarction group. This is 
essentially identical to the earlier series, and, there was little difference when 












Table 4.3: Clinical comparison 
 
 Histo 1970-2003 1996-2006 
Presentation time 


































Histo = histopathology, INF = infarction alone on histopathology examination, HINF 
= hemorrhage or hemorrhagic infarction on histopathological examination, GCS = 
Glasgow Coma Score 
 
When comparing outcomes the infarction group of patients had good outcomes in 
94% in the current series and 95% in the earlier series. However a much greater 
number of patients in the hemorrhage or hemorrhagic infarction group had a good 
outcome in the current series (84%) than in the earlier series (63%). Although the 
outcome is still not as good in the patients with infarction only, the difference is less 
marked. There were also no deaths in the current series, whereas there was 8% 
mortality in the hemorrhage or hemorrhagic infarction group in the earlier series. 
When visual function was compared, the outcome in the infarctive group in the 
current series was similar to the earlier series in that all the patients had a good 
outcome with normal vision or minor deficits. When comparing the group of patients 
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with hemorrhage or hemorrhagic infarction, there was an improvement from 73% to 
84% in functional vision between the earlier series and the current series. 
Nevertheless, 11% of patients in the current series in the hemorrhage or hemorrhagic 
infarction group remained blind. The endocrine replacement requirements remains 
unchanged between the different histopathological groups and series (Table 4.4.). 
 
Table 4.4: Comparison in outcome 
 










































Histo = histopathology, INF = infarction on histopathology, HINF = hemorrhage or 
hemorrhagic infarction on histopathology 
 
When the presentation, clinical features, and outcome of the current series are 
compared to the earlier series the infarction group of patients are very similar. The 
hemorrhage or hemorrhagic infarction group of patients, although still having a higher 
proportion of severe deficits and poor outcome than the infarction group have shown 
an improvement between the earlier and current series. Hemorrhage or hemorrhagic 
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infarction pituitary apoplexy is a more severe illness than pure infarctive apoplexy, 
and has a higher proportion of severe neurological deficits with a poorer outcome. 
The earlier series covers a thirty-year period, and during that time the clinical 
diagnosis, awareness of the disease, diagnostic modalities, surgical techniques and 
medical therapies have steadily improved. This is reflected in the improved outcome 





The features of infarction alone, or hemorrhage or hemorrhagic infarction on the 
histopathological examination correlate well with the operative findings, and the 
histopathological features can be accurately predicted from the MRI scan. There is a 
correlation between the histopathological groups regarding clinical presentation and 
outcome, with patients in the infarction group having a less severe presentation, 
normally a longer interval between ictus and presentation, and better outcome. The 
outcome of the hemorrhage or hemorrhagic infarction group has also improved as a 
result of modern imaging and improved surgical management. MRI is able to predict 
the histopathological diagnosis and consequently may help in improving the outcome 










CLINICAL RELEVANCE OF PRECIPITATING 





An increasing number of precipitating factors in pituitary apoplexy have been 
published, usually in the form of case reports or small series. These associated 
conditions have been linked to the apoplectic event and a variety of theories have 
been postulated [Biousse et al 2001]. In the majority of patients, there is no known 
pituitary adenoma, consequently the diagnosis is frequently difficult and may be 
delayed, which can result in a poor outcome for these patients.  A contemporary series 
of patients with pituitary apoplexy treated by the Department of Neurosurgery at the 
university of Virginia, in whom precipitating factors were identified, is reviewed in 
Chapter Five. 
 
5.2. Clinical material and methods 
 
The records of 38 patients who underwent surgery for pituitary apoplexy between 
January 1996 and March 2006 were retrospectively reviewed. The patients’ clinical 
features and radiological imaging were all consistent with pituitary apoplexy. All of 
the patients in this series had histological confirmation of pituitary apoplexy from 
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tissue obtained at surgery. Patients were assessed as having no precipitating factor if 
they were in their usual state of health when the apoplectic event occurred and no 
inciting agent or prodrome was identified. The presenting history, clinical findings, 
including visual function and opthalmoplegia, endocrine status, and outcome of the 
patients with precipitating factors was analyzed and compared with the patients in 
whom no precipitating factor could be identified. Data were analyzed using Stata 
Version 10.0 (Stata Corporation, College Station, Texas, USA). Proportions were 
compared using Fisher’s exact tests and odds ratios with 95% confidence intervals 
(CI). Continuous variables were described as means and medians, and compared with 
Wilcoxon rank-sum tests. All statistical tests are two-sided at alpha = 0.05. The 





Nine patients were identified as having precipitating factors for pituitary apoplexy. 
Twenty-nine patients had no precipitating factor identified. The predisposing factors 
that were identified in this series of patients were coronary artery surgery in two 
patients; hip replacement surgery, surgery for a benign testicular tumor, post-partum 
status in two patients, liver failure with associated disseminated intravascular 
coagulopathy, anticoagulant therapy, and subsequent to gamma knife surgery in a 
patient with Nelson’s syndrome (Table 5.1). A pituitary adenoma was identified in 






Table 5.1. The 9 patients in a contemporary series of 38 patients with pituitary 
apoplexy in whom a predisposing factor was identified.  
 
DIC = Disseminated Intravascular Coagulopathy. 
  
The mean age in patients with a predisposing factor was 48 years; in those without a 
predisposing factor, the mean age was 52.3 years. The ratio of women to men in the 
group with a predisposing factor was 5:4; in the group with no predisposing factor, 
the ratio was 11:18. Three patients (35%) with a predisposing factor had a known 
pituitary tumor (two pituitary macroadenomas that had been treated conservatively 
and a Nelson’s syndrome tumor), but only one (3.4%) patient had a known tumor in 
the group with no predisposing factor. Six of the nine (67%) patients with a 
predisposing factor presented with a very short apoplectic history of less than 1 day. 
All of the patients who had apoplexy after surgery presented immediately post-
operatively, and the patient who underwent gamma knife surgery presented within 12 
hours of undergoing treatment. The duration of symptoms before presentation to the 
neurosurgical department was more variable in those patients without any 
predisposing factor; eight patients (28%) presented within I day of their ictus, nine 
Patient 
no. 













Coronary artery surgery 
Hip surgery 
Liver failure / DIC 











































(31%) others presented within 1 week, and 12 (41%) presented after more than 1 
week. 
 
The clinical presentation of the two groups was compared. There was no difference 
between the clinical presenting features of patients who did and did not have a 
precipitating factor.  In the group of patients who had a precipitating factor, a larger 
proportion had an impaired level of consciousness at presentation than in the group 
without any precipitating factor. Three (33%) patients in the group with a 
precipitating factor had an impaired level of consciousness at the time of presentation 
compared with four (14%) in the group with no precipitating factor (p = 0.323). 
Visual function was normal in four patients (45%) in the group with a precipitating 
factor and in 15 (52%) in the group with no precipitating factor (p = 0.999). However, 
two of the nine patients (22%) in the group with a precipitating factor were blind at 
presentation compared with only one (3%) in patients in whom no precipitating factor 
was identified (p = 0.134). Opthalmoplegia was present in three (33%) patients in the 
precipitating factor group and seven (24%) in the no precipitating factor group (p = 
0.673). All the patients in whom a precipitating factor was present were found to have 
hypopituitarism, whereas hypopituitarism was present in 24 (83%) of those patients 








Table 5.2. Comparison of clinical presentation and histopathological studies 




The histopathological reports of the two groups of patients were compared. The group 
of patients with a precipitating factor were found to have hemorrhagic infarction in 
six cases (67%), hemorrhage alone in two (22%), and infarction alone in only one 
patient (11%). The single patient in whom infarction alone was seen had undergone 
gamma knife radiosurgery for Nelson’s syndrome. In the patients in whom there was 
no precipitating factor identified, the histopathological study showed infarction in the 
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11 patients (38%) (Table 5.2.).  Patients who had hemorrhage or hemorrhagic 
infarction were 13.1 times more likely to have precipitating factors compared to those 
with infarction alone (Odds Ratio = 13.1, p = 0.019, 95% CI: 1.35-612.2). 
 
Eight of the nine patients with a precipitating factor were followed-up. One patient 
discharged herself after surgery; thus, no follow-up data was available for that patient. 
The mean length of follow-up period was 25 months. Four (50%) of the patients were 
normal at the time of follow-up evaluation, three had a minor visual deficit, and one 
(12.5%) had a major neurological deficit (blindness). The visual function of these 
patients at the time of follow-up evaluation was normal in six (75%), not normal but 
functional in one (12.5%), and one patient remained blind (12.5%). Three patients 
(37.5%) had residual opthalmoplegia / paresis at the time of follow-up evaluation. 
The twenty-nine patients in whom no precipitating factor was identified were 
followed for a mean of 32 months. Nineteen (66%) of these patients were normal at 
the time of the follow-up evaluation with no deficits, seven (24%) had a minor 
neurological deficit, and 3 (10%) had major neurological deficits. When their visual 
outcome was assessed, 22 (76%) had normal visual function, visual function was 
improved but not normal in six (21%) patients, and one (3%) patient remained blind.  
Six patients (21%) had residual opthalmoplegia / paresis. All of the patients in the 
group with a precipitating factor who had follow-up remained hypopituitary requiring 
hormone replacement therapy, whereas 24 (83%) of the patients with no precipitating 
factor required replacement therapy.  The presence or absence of a precipitating factor 
was not significantly associated with outcome (p = 0.725), visual function (p = 






Although the pathogenesis of pituitary apoplexy is not well understood, there have 
been numerous precipitating factors proposed that might trigger pituitary apoplexy. 
These factors have been described as precipitating or associated factors [Biousse et al 
2001]. Associated factors suggest that they are not necessarily direct causes, but that 
their presence may make the tumor more susceptible to the development of pituitary 
apoplexy. Precipitating factors, however, suggest that these factors directly trigger the 
pathogenesis of apoplexy in pituitary tumors. 
 
The majority of reported cases of precipitating factors for pituitary apoplexy are in the 
form of case reports, which makes it difficult to determine the proportion of patients 
with pituitary apoplexy who may have a precipitating factor. There is a lack of 
uniform agreement regarding what constitutes a precipitating factor. In addition, we 
cannot always be certain that there is no precipitating factor present simply because it 
may not have been recognized. In the current series, nine out of thirty-eight patients 
(24%) had a precipitating factor identified. The majority of patients who present with 
pituitary apoplexy do not have a precipitating factor, and there is a wide variation of 
incidence of reported precipitating factors ranging from 4% to 30% [Cardoso & 
Petersen 1984, Randeva et al 1999]. 
 
Biousse et al [2001] divide the precipitating factors into four categories: 1) those 
associated with reduced blood flow, 2) acute increase in blood flow, 3) stimulation of 
the pituitary gland, and 4) the anticoagulated state. The published case reports and 
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series in the English literature from 1990 to 2006 were reviewed, and 97 patients were 
found in whom a precipitating factor was reported. For the purposes of this discussion 
they were divided into stimulation of the pituitary gland (32 patients), surgery (40 
patients), anticoagulant therapy (13 patients), head injury (3 patients), and other 
miscellaneous causes (eight patients) (Figure 5.1) 
 
Figure 5.1. Bar graph showing the precipitating factors in pituitary apoplexy 
published in the English-language literature between 1990 and 2006. Pit. Stim. = 
stimulation of the pituitary tumor / gland, Anticoag. = anticoagulant therapy. 
 
Stimulation of the pituitary gland or tumor may be the result of pregnancy, pituitary 
stimulation testing, treatment of prolactinomas with cabergoline or bromocriptine, or 
pituitary stimulation secondary to treating other conditions with gonadotrophin-







































had apoplexy in late pregnancy, possibly related to increased pituitary stimulation 
resulting from increased estrogens [Biousse et al 2001, de Heinde et al 2004]. Two of 
the patients in the current series had apoplexy shortly after childbirth, one of them 
after a caesarian section. The rapid growth of pituitary tumors is well described 
during pregnancy. It is possible that the relative ischemia related to outgrowing the 
blood supply and increased pituitary stimulation may combine to precipitate 
apoplexy. Fifteen patients with a known pituitary tumors developed pituitary 
apoplexy after pituitary stimulation tests in the literature review. None of the patients 
in the current series had pituitary stimulation tests as a precipitating factor. 
Stimulatory tests that have been implicated include thyrotropin-releasing hormone, 
corticotrophin-releasing hormone, gonadotrophin-releasing hormone, insulin, and 
luiteinizing hormone-releasing hormone [Chapman et al 1985, Dokmetas et al 1999, 
Galvin & Stavern 2004, Hiroi et al 2001, Lee et al 2000, Matsuura et al 2001, Otsuka 
et al 1998, Riedl et al 2000, Rotman-Pikielny et al 2003, Szaboics et al 1997, Vassello 
et al 1994]. It has been speculated that the stimulation tests may have a vaso-active 
effect that initially results in ischemia and infarction that later may evolve into 
hemorrhage [Matsuura et al 2001]. The use of cabergoline and bromocriptine in the 
treatment of prolactinomas have also been described as precipitating factors [Cardoso 
& Petersen 1984, Knoepfelmacher et al 2004]. The use of gonadotrophin-releasing 
hormone analogs or agonists in patients for the treatment of prostate carcinoma and 
ovarian stimulation in patients who have an undiagnosed pituitary tumor can also 
result in pituitary apoplexy [Davis et al 2006, Engel et al 2003, Morsi et al 1996, 
Reznik et al 1997]. The treatment of infertility with clomiphene stimulation has also 
been implicated [Walker et al 1996]. 
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Forty patients in whom surgery was implicated as a precipitating factor were found in 
the literature review. Twenty-two of these cases involved cardiac surgery, six 
pituitary surgeries for large tumors, 11 other surgical procedures, and one spinal 
anesthetic. In the current series, two patients developed apoplexy immediately after 
cardiac surgery, one after hip surgery, and one after orchidectomy for a testicular 
mass. Factors that may predispose patients with a pituitary tumor to apoplexy who 
undergo surgery include hypotension and fluctuations in blood pressure, transient 
increases in intracranial pressure, thrombotic events, dilution of blood from the use of 
crystalloids, and revascularization surgery [Abbott & Kirby 2004, Biousse et al 2001, 
Cardoso & Petersen 1984, Cohen et al 1997, Cummings et al 1997, Khandelwai et al 
2005, Liberale et al 2006, Liu et al 2001, Mattke et al 2002, Peck et al 1980, Pliam et 
al 1995, Randeva et al 1999]. Patients undergoing cardiac surgery seem to be at 
higher risk than patients undergoing other types of surgery. This may be the result of 
the frequent use of anticoagulant therapy, cardiac bypass, and more severe 
hypotension in this type of surgery [Abbott & Kirby 2004, Alzetani et al 2002, 
Bhattacharyya et al 1999, Cummings et al 1997, Pliam et al 1995, Wiessman et al 
1999]. Pituitary apoplexy has been reported in patients who have very large pituitary 
tumors and have undergone partial resection. This surgery may compromise the blood 
supply to the remaining tumor resulting in apoplexy, associated with a high mortality 
rate [Ahmad et al 2005, Lee & Reilly 2001]. Abdominal aneurysm surgery, hip and 
knee joint replacement surgery, spinal surgery, abdominal surgery, and large-volume 
liposuction have been associated with pituitary apoplexy [Acar & Mertol 2004, 
Cardoso & Petersen 1984, Cohen et al 2004, Galvin & Stavern 2004, Khandelwai et 
al 2005, Liberale et al 2006, Liu et al 2001, Mattke et al 2002]. Spinal anesthesia, on 
 90 
the basis of lowering intracranial pressure and producing hypotension, has been 
implicated in precipitating pituitary apoplexy [Lennon et al 1998]. 
 
Thirteen patients in the literature review had anticoagulation or coagulopathy 
identified as a precipitating factor. In the current series, a woman with coagulopathy 
secondary to chronic liver disease had pituitary apoplexy. The use of an anticoagulant 
or thrombolytic agent for the treatment of acute myocardial infarction in a patient 
with an undiagnosed pituitary adenoma has been implicated as a precipitating factor 
in pituitary apoplexy [Fuchs et al 1998, Karotinsky et al 2002, Maiza et al 2004, 
Nagarajan et al 2002, Oo et al 1997, Skijarevski et al 2003, Tan et al 2007, 
Williamowicz & Houlden 1999]. Fluctuations of blood pressure and increased stress 
on the pituitary gland can also be precipitating factors in patients with myocardial 
infarction [Biousse et al 2001]. Anticoagulation with heparin for dialysis and 
idiopathic thrombocytopenia have also been implicated as precipitating factors  [De la 
Torre et al 1998, Lenthal et al 2001, Maiza et al 2004]. 
 
Three cases of pituitary apoplexy after head injury were reported in the literature 
review. A possible mechanism postulated was that the intrasellar part of the tumor 
may be fixed to the bony structure of the sella. The suprasellar part is relatively free to 
move so that rotational forces will create a shearing strain between the intra- and 
suprasellar part of the tumor resulting in ischemic injury and apoplexy [Uchiyama et 
al 1999]. The raised intracranial pressure and episodes of hypotension that are often 
associated with a head injury can also be contributing factors. Carotid artery injury or 
vasospasm has also been associated with pituitary apoplexy [Itoyama et al 1990, 
Provenzale et al 1995]. 
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In the current series a single patient who received gamma knife irradiation for 
Nelson’s syndrome developed apoplexy within 12 hours; a similar case was published 
in the review of the literature. Two cases of pituitary apoplexy after coronary artery 
angiography and one after cerebral angiography have been described. The 
pathogenesis may relate to the use of heparin in coronary angiography and alterations 
in perfusion from blood pressure fluctuations [Louwerens et al 1996, Skijarevski et al 
2003]. Other published reports of possible precipitating factors include gadolinium-
enhanced MRI scans, subarachnoid hemorrhage, physical exertion, lymphocytic 
leukemia, metastatic endometrial carcinoma, and cellulitis [Biousse et al 2001, Proust 
et al 1995, Randeva et al 1999, Wichers et al 1997]. 
 
Biousse et al [2001] found that an altered level of consciousness was more common 
in patients with a precipitating factor compared to those without, but they were unable 
to explain this difference. The rest of the clinical presentation was similar in their two 
groups of patients. In the current series, there seems to be a somewhat more severe 
presentation in those patients with a precipitating factor. Thirty-three percent of 
patients in whom a precipitating factor was identified had a diminished level of 
consciousness compared with 14% in those without a precipitating factor. Blindness 
was present in 22% of patients on presentation with a known precipitating factor 
compared with 3% in those without, and a slightly lower percentage of those with a 
precipitating factor had normal vision. A higher proportion of patients in the 
precipitating factor group had opthalmoplegia (33%) compared with those without 
(24%). No statistically significant difference was identified in the clinical features 
between those patients with and without a precipitating factor. However, the relatively 
 92 
small sample size in statistical terms (although not in terms of pituitary apoplexy) 
limits the interpretation of statistical significance. Although most of the patients 
without a precipitating factor were hypopituitary (83%), all of those with a 
precipitating factor were found to be hypopituitary on endocrine testing. 
 
The histopathological examinations of the tumors at the time of surgery showed 
differences between the two groups. Of importance is that the entire specimen is sent 
for histopathological examination so an incorrect diagnosis is minimized. Only one 
patient in the group of patients with a precipitating factor showed ischemic infarction 
alone. Eighty-three percent of patients had a picture of mixed hemorrhage and 
infarction or hemorrhage alone on histopathological examination. In the group of 
patients with no precipitating factor, the majority was found to have infarction alone 
(68%) on histopathological studies with a minority (38%) having a mixed picture of 
hemorrhagic infarction. Patients with hemorrhage or hemorrhagic infarction are 13.1 
times more likely to have a precipitating factor compared to those with infarction 
alone. In Chapter 3 it was shown that patients who presented with histological 
features of infarction alone had less severe clinical features on presentation, a longer 
course before presentation, and a better outcome than those presenting with 
hemorrhagic infarction or frank hemorrhage. Therefore, logically it follows that a 
more severe clinical presentation and poorer outcome would be expected in patients 
in whom a precipitating factor is identified. The current series of patients was also 
analyzed for histopathological findings (Chapter 4) and a similar trend is shown 
except that the outcomes of those patients with hemorrhagic infarction or hemorrhage 
alone have improved compared to the earlier study, although they are still not as good 
as the infarctive group. 
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One of the major problems in pituitary apoplexy is that it most frequently occurs in a 
patient with an undiagnosed pituitary tumor and, therefore, the diagnosis may easily 
be missed or delayed. In patients who have a known pituitary tumor and are 
undergoing pituitary endocrine investigations, the diagnosis of pituitary apoplexy may 
be easier. In the majority of these patients, there is another primary illness, or surgery 
has been performed for another pathology, and the patient presents with neurological 
or visual impairment that is not obviously caused by the known pathology. In 
addition, pituitary apoplexy is not a common event, which may further delay the 
diagnosis or cause it to be missed altogether. Therefore, it is important when patients 
develop neurological / visual or endocrine disturbances after illnesses or surgery that 
cannot be explained by the primary diagnosis or complication, particularly when the 
diagnosis is known to be a precipitating factor of pituitary apoplexy, they should be 
evaluated promptly using MRI scans and endocrine assessment. This is particularly 
important because untreated apoplexy may result in death or major deficits. 
 
The knowledge of precipitating factors that can result in apoplexy of a pituitary tumor 
may have some influence on the management of patients with or without known 
pituitary tumors. In a patient with a known pituitary tumor, there is a risk in 
performing pituitary stimulation tests [Vassallo et al 1994]. In patients who are to 
receive gonadotrophin-releasing hormone agonists in the treatment of prostatic 
carcinoma, an argument can be made for performing an MRI scan to exclude pituitary 
tumor. If a patient has a diagnosed pituitary tumor and is to undergo treatment that is 
a known precipitating factor such as anticoagulation or coronary artery surgery, the 
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risk should be made known to both the patient and treating physicians; in certain 




Pituitary apoplexy may be associated with precipitating factors in a minority of cases. 
The most commonly associated precipitating factors are surgery, particularly coronary 
artery surgery, pituitary stimulation tests, and anticoagulation. The pathogenesis of 
pituitary apoplexy and the precipitating factors are not completely understood. The 
histology of apoplectic pituitary tumors in which precipitating factors are identified is 
predominantly hemorrhagic infarction or hemorrhage. The presence of a precipitating 
factor makes hemorrhage or hemorrhagic infarction 13.1 times more likely, and this 
may influence the severity of presentation and outcome. Care should be taken when 
performing stimulation tests on a patient with a pituitary tumor, placing a patient with 
a pituitary tumor on anticoagulant therapy, or undertaking coronary artery surgery or 
other surgery. In patients who have pathology or who undergo a procedure that is a 
known precipitating factor in pituitary apoplexy and who developed an impairment in 
their level of consciousness, visual deficits, or endocrine failure should undergo 

















6.1. Researching uncommon clinical problems is problematic so the methodology of 
setting up a website using a common protocol and having different institutions 
entering patients is a very useful tool for collecting data from more than a single 
institution. It allows for a wider experience in terms of patient numbers as well as 
encompassing the different possible approaches.  
 
6.2. A study group of 62 patients with pituitary apoplexy from University of Cape 
Town and University of Virginia was retrospectively analyzed. In the majority of 
patients the pituitary adenoma was undiagnosed and the apoplexy was the first 
presentation. The diagnosis is easy to miss and a high index of suspicion is necessary 
in patients presenting with headache, visual acuity and field defects, opthalmoplegia, 
or diminished level of consciousness. MRI scan is the imaging modality of choice. In 
this series 59 patients were treated surgically and in the majority a good outcome was 
achieved. High dose corticosteroid replacement is necessary in all patients. 
Emergency transsphenoidal decompression should be carried out on all patients with 
diminished level of consciousness, hypothalamic disturbance or severe visual 
impairment including blindness. In patients with mild or moderate visual impairment 
surgery should be performed as soon as possible (within the first week). There is 
evidence that some patients, in particular those with isolated opthalmoplegia or those 
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who only present long after the ictus with mild or improving symptoms, may be 
managed conservatively. The majority of patients require long-term replacement 
therapy. 
 
6.3. The GSH-UVA cohort of patients was divided on the basis of histopathology into 
2 groups: infarction alone; or hemorrhage or hemorrhagic infarction. Patients who 
presented with pituitary apoplexy due to infarction alone in a pituitary adenoma were 
found to have a statistically significant more benign illness with a less severe 
presentation and better outcome than those in whom histopathological studies showed 
hemorrhagic infarction or hemorrhage alone. 
 
6.4. Thirty-six patients who had MRI scans to diagnose pituitary apoplexy at UVA 
and underwent surgery were retrospectively reviewed to ascertain if MRI could 
predict histolopathological findings. The histological features of infarction alone, or 
hemorrhage or hemorrhagic infarction on the histopathological examination was 
accurately predicted on the MRI. MRI can predict the histolopathological diagnosis 
and this may help in management decisions and improving the outcome of these 
patients in the future. 
 
6.5. In a minority of cases pituitary apoplexy may be associated with precipitating 
factors the most common of which are surgery, anticoagulation and pituitary 
stimulation tests. The histopathology of apoplectic tumors in which precipitating 
factors were identified are 13.1 times more likely to be hemorrhagic or hemorrhagic 
infarction and this may influence the severity and the outcome of pituitary apoplexy. 
 
 97 
6.6. The uniqueness of this thesis is that this is the first time that it has been shown 
that MRI at the time of diagnosis can be used to predict the histopathology and 
consequently the severity as well as the outcome in pituitary apoplexy. In addition the 
presence of a precipitating factor may also help in predicting outcome in these 
patients. This has significant benefit in managing patients with pituitary apoplexy, 
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